UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

		X	
		:	
In re:		:	Chapter 11 Case No.
		:	
SIGA TECHNOLOGIES, INC.,		:	14-12623 (SHL)
		:	
		:	
	Debtor.	:	
		:	
		\mathbf{X}	

SCHEDULES OF ASSETS AND LIABILITIES

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 2 of 42

SIGA TECHNOLOGIES, INC. GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY, AND DISCLAIMERS REGARDING DEBTOR'S SCHEDULES OF ASSETS AND LIABILITIES AND STATEMENT OF FINANCIAL AFFAIRS October 30, 2014

GENERAL NOTES:

These Global Notes and Statement of Limitations, Methodology, and Disclaimers Regarding the Debtor's Schedules of Assets and Liabilities and Statement of Financial Affairs (the "Global Notes") are incorporated by reference in, and comprise an integral part of, the Schedules of Assets and Liabilities and Statement of Financial Affairs, and should be referred to and considered in connection with any review thereof.

The Schedules of Assets and Liabilities (each, a "Schedule" and, collectively, the "Schedules") and the Statement of Financial Affairs ("SOFA") filed by SIGA Technologies, Inc. ("SIGA" or the "Debtor") in this chapter 11 case pending in the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court") were prepared, pursuant to section 521 of chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") and Rule 1007 of the Federal Rules of Bankruptcy Procedure, by management of the Debtor, with the assistance of the Debtor's Court-appointed advisors. Financial information is presented on an unaudited basis. While the Debtor's management has made every reasonable effort to ensure that the Schedules and SOFA are as accurate and complete as possible under the circumstances, based on information that was available to them at the time of preparation, subsequent information or discovery may result in material changes to these Schedules and SOFA, and inadvertent errors or omissions may have occurred. Because the Schedules and SOFA contain unaudited information, which is subject to further review, verification, and potential adjustment, there can be no assurance that these Schedules and SOFA are complete. The Debtor reserves all rights to amend the Schedules and SOFA from time to time, in all respects, as may be necessary or appropriate, including, but not limited to, the right to dispute or otherwise assert offsets or defenses to any claim reflected in the Schedules and SOFA as to amount, liability, or classification, or to otherwise subsequently designate any claim as "disputed," "contingent," or "unliquidated." Furthermore, nothing contained in the Schedules and SOFA shall constitute a waiver of rights with respect to this chapter 11 case, including, but not limited to, issues involving assumption or rejection of contracts under the provisions of chapter 5 of the Bankruptcy Code, substantive consolidation, equitable subordination, defenses, and/or causes of action arising under the provisions of chapter 5 of the Bankruptcy Code and other relevant non-bankruptcy laws to recover assets or avoid transfers.

The Schedules and SOFA have been signed by Daniel Luckshire, Chief Financial Officer of the Debtor. Mr. Luckshire assumed the role of Chief Financial Officer of the Debtor in February 2011. Accordingly, in reviewing and signing the Schedules and SOFA, Mr. Luckshire necessarily relied upon the efforts, statements, and representations of the Debtor's other personnel and professionals. Mr. Luckshire has not (and could not have) personally verified the accuracy of each such statement and representation, including, for example, statements and representations concerning amounts owed to creditors, classification of such amounts, and such creditors' addresses.

The Schedules, SOFA, and Global Notes should not be relied upon by any persons for information relating to current or future financial conditions, events, or performance of the Debtor.

<u>Description of the Case.</u> On September 16, 2014 (the "Commencement Date"), the Debtor commenced a case under chapter 11 the Bankruptcy Code in the Bankruptcy Court. The Debtor's chapter 11 case was assigned case number 14-12623 (SHL). The Debtor's fiscal year ends on December 31. Unless otherwise noted, all asset information contained in the Schedules and SOFA is presented as of August 31, 2014 and all liability information is presented as of the close of business on September 15, 2014. The Debtor continues to operate its business and manage its assets as a debtor in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 3 of 42

Basis of Presentation. These Schedules and SOFA do not purport to represent financial statements prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), nor are they intended to fully reconcile to the financial statements prepared by the Debtor. Although the Debtor has made reasonable efforts to correctly quantify, characterize, classify, categorize, and designate the claims, assets, executory contracts, unexpired leases, and other items reported in the Schedules and SOFA, inadvertent errors or omissions may exist. In addition, certain items reported in the Schedules and SOFA could be included in more than one category. In those instances, one category has been chosen to avoid duplication. Further, the designation of a category is not meant to be wholly inclusive or descriptive of the rights or obligations represented by such item. Moreover, the categories are included for ease of reference and are not controlling. Information contained in the Schedules and SOFA has been derived from the Debtor's books and records and historical financial statements.

Amendment. Reasonable efforts have been made to prepare and file complete and accurate Schedules and SOFA. Despite these efforts, inadvertent errors or omissions may exist. The Debtor reserves all rights, but is not required, to amend and/or supplement the Schedules and SOFA from time to time as is necessary and appropriate.

<u>Confidential or Sensitive Information.</u> There may be instances in which certain information in the Schedules and SOFA intentionally has been redacted because of the nature of an agreement between the Debtor and a third party, concerns about the confidential or commercially sensitive nature of certain information, or concerns for the privacy of an individual. The alterations will be limited to only what is necessary to protect the Debtor or third party and will provide parties in interest who have a reasonable basis for review of such information with sufficient information to discern the nature of the listing.

<u>Causes of Action</u>. Despite its reasonable efforts to identify all known assets, the Debtor may not have listed all of its causes of action or potential causes of action against third parties as assets in its Schedules and SOFA, including, but not limited to, avoidance actions arising under chapter 5 of the Bankruptcy Code and actions under other relevant non-bankruptcy laws to recover assets. The Debtor reserves all of its rights with respect to any claims, causes of action, or avoidance actions it may have, and neither these Global Notes nor the Schedules and SOFA shall be deemed a waiver of any such claims, causes of actions, or avoidance actions or in any way prejudice or impair the assertion of such claims.

<u>Recharacterization.</u> The Debtor has made reasonable efforts to correctly characterize, classify, categorize, and designate the claims, assets, executory contracts, unexpired leases, and other items reported in the Schedules and SOFA. However, the Debtor may have improperly characterized, classified, categorized, or designated certain items. The Debtor thus reserves all of its rights to recharacterize, reclassify, recategorize, or redesignate items reported in the Schedules and SOFA at a later time as necessary or appropriate as additional information becomes available.

<u>Claim Description</u>. Any failure to designate a claim in the Schedules or SOFA as "contingent," "unliquidated," or "disputed" does not constitute an admission by the Debtor that such claim or amount is not "contingent," "unliquidated," or "disputed." The Debtor reserves all of its rights to dispute, or to assert offsets or defenses to, any claim reflected on its Schedules or SOFA on any grounds, including, but not limited to, amount, liability, priority, status, or classification, or to otherwise subsequently designate any claim as "contingent," "unliquidated," or "disputed." Moreover, the Debtor reserves all of its rights to amend its Schedules and SOFA as necessary and appropriate, including, but not limited to, with respect to claim description and designation.

<u>Unliquidated Claim Amounts</u>. Claim amounts that could not be quantified readily by the Debtor are scheduled as "unliquidated." The description of an amount as "unliquidated" is not intended to reflect upon the materiality of such amount.

<u>Bankruptcy Court Orders</u>. Pursuant to certain orders of the Bankruptcy Court entered in the Debtor's chapter 11 case (the "**First-Day Orders**"), the Debtor was authorized (but not directed) to pay, among other things, certain prepetition claims of employees, taxing authorities, critical vendors, reimbursed vendors, insurance companies, and certain other prepetition creditors. Accordingly, these liabilities may be, or have been, satisfied in accordance with such orders and therefore may not be listed in the Schedules and SOFA.

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 4 of 42

<u>Valuation</u>. It would be prohibitively expensive, unduly burdensome, and an inefficient use of estate assets for the Debtor to obtain current market valuations of all of its assets. Accordingly, unless otherwise indicated, the Schedules and SOFA reflect net book values as of August 31, 2014. Exceptions to this include operating cash and certain other assets. Operating cash is presented at bank balances as of the Commencement Date. Certain other assets, such as investments in subsidiaries and other intangible assets, are listed at unliquidated amounts, as the net book values may differ materially from fair market values. Amounts ultimately realized may vary from net book value (or whatever value was ascribed), and such variance may be material. Accordingly, the Debtor reserves all of its rights to amend or adjust the value of each asset set forth herein. In addition, the amounts shown for total liabilities exclude items identified as "unliquidated" and, thus, ultimate liabilities may differ materially from those stated in the Schedules and SOFA.

<u>Dates</u>. The information provided herein, except as otherwise noted, represents the asset data of the Debtor as of August 31, 2014 and the liability data of the Debtor as of the close of business on September 15, 2014. The Debtor chose August 31, 2014 as the date by which to reflect asset information as it was the most current month end for the Debtor's accounting system immediately preceding the Commencement Date, and the net book values should not have changed materially between August 31, 2014 and the close of business on September 15, 2014.

<u>Specific Notes</u>. These General Notes are in addition to the specific notes set forth in the Schedules and SOFA. Disclosure of information in a Schedule, a response to a particular SOFA Question, or an exhibit or attachment to a Schedule or SOFA, even if incorrectly placed, shall be deemed to be disclosed in the correct Schedule, SOFA Question, exhibit, or attachment.

<u>Liabilities</u>. The Debtor has sought to allocate liabilities between the prepetition and postpetition periods based on the information and research that was conducted in connection with the preparation of the Schedules and SOFA. As additional information becomes available and further research is conducted, the allocation of liabilities between prepetition and postpetition periods may change. Liabilities are generally listed as of the Commencement Date, unless otherwise described herein. The Debtor reserves the right, but is not required, to amend the Schedules and SOFA as it deems appropriate in this regard.

Excluded Assets and Liabilities. The Debtor has excluded certain categories of assets, tax accruals, and liabilities from the Schedules and SOFA, including goodwill; deferred tax assets; and deferred revenue; accrued liabilities including, but not limited to, accrued employee compensation and employee benefits; tax accruals; accrued accounts payable; and assets with a net book value of zero. The Debtor also has excluded rejection damage claims of counterparties to executory contracts and unexpired leases that may be rejected, to the extent such damage claims exist. In addition, certain immaterial assets and liabilities may have been excluded. Pursuant to certain First-Day Orders, the Debtor was authorized (but not directed) to pay, among other things, certain prepetition claims of employees, taxing authorities, critical vendors, reimbursed vendors, insurance companies, and certain other prepetition creditors. Accordingly, these liabilities may be, or have been, satisfied in accordance with such orders and therefore may not be listed in the Schedules and SOFA.

<u>Leases</u>. The Debtor has not included in the Schedules and SOFA the future obligations of any capital or operating leases. Capital leases are not included as assets of the Debtor on Schedule A or B. Capital leases are only reported on Schedule G. To the extent that there was an amount outstanding under a lease as of the Commencement Date, the amount owed to that creditor has been listed on Schedule F.

<u>Receivables.</u> For confidentiality reasons the Debtor has not listed individual customer accounts receivable balance information. Accounts receivable information has been listed net of reserves for doubtful accounts and returns as of August 31, 2014.

<u>Intellectual Property Rights</u>. Exclusion of certain intellectual property shall not be construed to be an admission that such intellectual property rights have been abandoned, have been terminated, or otherwise have expired by their terms, or have been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction. Conversely, inclusion of certain intellectual property shall not be construed to be an admission that such intellectual property rights have not been abandoned, have not been terminated, or otherwise have not expired by their terms, or have not been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction.

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 5 of 42

Accordingly, the Debtor reserves all of its rights with respect to the legal status of any and all intellectual property rights.

Fiscal Year. The Debtor's fiscal year ends on December 31.

<u>Property and Equipment</u>. Unless otherwise indicated, owned property and equipment are stated at net book value. The Debtor may lease furniture, fixtures, and equipment from certain third party lessors. Any such leases are set forth in the Schedules and SOFA. Nothing in the Schedules and SOFA is or shall be construed as an admission as to the determination as to the legal status of any lease (including whether any lease is a true lease or a financing arrangement), and the Debtor reserves all of its rights with respect to same.

<u>Interest in Subsidiary and Affiliate.</u> The Debtor owns all of the stock of its sole subsidiary and profit interest units in an affiliate entity, neither of which are debtors.

Insiders. The Debtor has attempted to include all payments made over the twelve (12) months immediately preceding the Commencement Date to any individual or entity deemed an "insider." For these purposes, "insider" is defined as (i) directors of the Debtor; (ii) officers of the Debtor; (iii) persons in control of the Debtor; (iv) partnership in which the Debtor is a general partner; (v) general partner of the Debtor; or (vi) relative of a general partner, director, officer, or person in control of the Debtor. The listing of a party as an "insider," however, is not intended to be, nor shall be, construed as a legal characterization of such party as an insider and does not act as an admission of any fact, claim, right, or defense, and all such rights, claims, and defenses are hereby expressly reserved. Further, the Debtor does not take any position concerning (a) the person's influence over the control of the Debtor, (b) the person's management responsibilities or functions, (c) the person's decision-making or corporate authority, or (d) whether the person could successfully argue that he or she is not an insider under applicable law, including the federal securities laws, for any theories of liability or for any other purpose.

<u>Totals.</u> All totals that are included in the Schedules and SOFA represent totals of all the known amounts included in the Schedules and SOFA and exclude items identified as "unliquidated." To the extent there are unliquidated amounts, the actual totals may be materially different from the listed totals.

SPECIFIC NOTES WITH RESPECT TO DEBTOR'S SCHEDULES:

Schedule A: Real Property

The Debtor does not own any real property.

Schedule B-1: Petty Cash

Petty cash is listed in the Schedules at net book values.

Schedule B-2: Operating Cash

Operating cash is presented at bank balances as of the Commencement Date for each bank account.

Schedule B-3: Deposits

Each deposit amount and the party holding the deposit is listed.

Schedule B-13: Investments in Incorporated and Unincorporated Businesses

Investments in non-publicly traded companies are listed at unliquidated amounts because the net book values may not closely approximate the fair market values.

Schedule B-16: Accounts Receivable

Accounts receivable represent trade accounts receivable and are listed as one amount for each entity. Customer detail is not provided because providing such detail could disclose confidential information. Amounts are based on the net book value as of August 31, 2014.

Schedule B-18: Other Liquidated Debts Owed to the Debtor

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 6 of 42

In the ordinary course of business the Debtor has generated various tax refunds as a result of operating losses. Tax refunds are reported by taxing authority.

Schedule B-22: Patents, Copyrights, and Other Intellectual Property

The list of intellectual property items (patents, copyrights, trade names, etc.) are listed at unliquidated amounts. In addition to the items listed herein, the Debtor owns various other intellectual property, including trade secrets and other proprietary information related to the research and development of new therapeutics or vaccines, that is not listed in the Debtor's accounting books and records and, therefore, not included herein.

Schedule B-23: Licenses, Franchises, and Other Intangibles

Schedule G sets forth a licensing agreement, which either may be in addition to, or duplicative of, the licenses set forth on Schedule B-23. The inclusion of any license agreement in both Schedules B-23 and G should not be deemed to be an indication or admission of the existence of multiple agreements. Similarly, the exclusion of any license agreement from either Schedule B-23 or Schedule G should not be deemed determinative of whether the license is an executory contract or simply a grant of property rights. The Debtor expressly reserves the right to recharacterize these agreements, as appropriate, upon further review. The information provided in response to Schedule B-23 (if any) does not include the Debtor's general business licenses.

Schedule B-28: Office Equipment

Office equipment is categorized by type and presented at net book value.

Schedule B-29: Machinery and Equipment

Equipment used in the Debtor's business is provided categorically and presented at net book value.

Schedule B-35: Other Assets

Other assets primarily include certain investments and various other assets, which are presented categorically. This section includes various prepaid expenses, including insurance, deposits, retainers, and other items as of August 31, 2014.

Schedule D – Creditors Holding Secured Claims.

Amounts listed herein are as of the Commencement Date.

Except as otherwise agreed pursuant to a stipulation, agreed order, or general order entered by the Bankruptcy Court, the Debtor reserves its rights to dispute or challenge the validity, perfection, or immunity from avoidance of any lien purported to be granted or perfected in any specific asset to a secured creditor listed on Schedule D. Moreover, although the Debtor may have scheduled claims of various creditors as secured claims, the Debtor reserves all rights to dispute or challenge the secured nature of any such creditor's claim or the characterization or structure of any such transaction, or any document or instrument (including, without limitation, any intercompany agreement) related to such creditor's claim. The descriptions provided on Schedule D are intended only to be a summary; they do not constitute an admission and are not dispositive for any purpose. Reference to the applicable loan agreements and related documents is necessary for a complete description of the collateral and the nature, extent, and priority of any lien. Nothing in the Global Notes or the Schedules and SOFA shall be deemed to be an admission, modification, or interpretation of or relating to such agreements.

To the extent that any landlords, real property and personal property lessors, utility companies, insurance companies, or other creditors hold a security deposit from the Debtor and to the extent that such deposits constitute secured claims, such deposits are not listed on Schedule D, except as specifically stated herein.

Schedule E – Creditors Holding Unsecured Priority Claims.

Amounts listed herein are as of the Commencement Date.

All claims listed on Schedule E are claims owed to various taxing authorities. The listing of any claim on Schedule E does not constitute an admission by the Debtor that such claim is entitled to priority treatment under

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 7 of 42

section 507 of the Bankruptcy Code. The Debtor reserves all of its rights to dispute the amount and/or the priority status of any claim on any basis at any time.

As noted in the Global Notes, the Bankruptcy Court entered a First-Day Order granting (but not directing) the Debtor to pay certain prepetition employee wage and other obligations in the ordinary course (the "Employee Wage Order"). Pursuant to the Employee Wage Order, the Debtor believes that any priority employee claims for prepetition amounts have been or will be satisfied, and such satisfied amounts therefore are not listed on Schedule E.

Certain of the tax claims may be subject to ongoing audits, and the Debtor otherwise is unable to determine with certainty the amount of many, if not all, of the remaining claims listed on Schedule E. Therefore, the Debtor has listed all such claims as unliquidated in amount, pending final resolution of ongoing audits or outstanding issues. Taxes listed here primarily include sales and use tax, personal and real property tax, franchise tax, business license fees, and excise tax. These taxes may be paid in connection with First-Day Orders. Therefore, the taxing authorities for which the Debtor has paid for these types of taxes in the past are listed in the Schedules at \$0 and marked as contingent and unliquidated.

Finally, the Debtor reserves its right to object to any listed claims on the ground that, among other things, such claims have already been satisfied.

Schedule F – Creditors Holding Unsecured Nonpriority Claims.

Amounts listed herein are as of the Commencement Date.

The Debtor has used reasonable best efforts to list all general unsecured claims against the Debtor on Schedule F based upon the Debtor's existing books and records.

Schedule F does not include certain deferred revenue, deferred credits, deferred charges, deferred liabilities, accruals, or general reserves. Such amounts are general estimates of liabilities and do not represent specific claims as of the Commencement Date. However, such amounts are reflected on the Debtor's books and records as required in accordance with GAAP. Such accruals are general estimates of liabilities and do not represent specific claims as of the Commencement Date.

After the Commencement Date, the Debtor requested that its vendors provide the Debtor with any outstanding amounts due and that have not yet been invoiced. To the extent those amounts were provided to the Debtor, they are included on Schedule F.

The claims listed on Schedule F arose or were incurred on various dates. In certain instances, the date on which a claim arose is an open issue of fact. Although commercially reasonable efforts have been made to identify the date of incurrence of each claim, determining the date upon which each claim on Schedule F was incurred or arose would be unduly burdensome and cost prohibitive and, therefore, no date is listed for such claims listed on Schedule F.

Schedule F reflects the prepetition amounts owing to counterparties to executory contracts and unexpired leases. Such prepetition amounts, however, may be paid in connection with the assumption, or assumption and assignment, of an executory contract or unexpired lease. In addition, Schedule F does not include rejection damage claims of the counterparties to the executory contracts and unexpired leases that have been or may be rejected, to the extent such damage claims exist.

Pursuant to the First-Day Orders, the Debtor was authorized (but not directed) to pay, among other things, certain prepetition claims of employees, taxing authorities, critical vendors, reimbursed vendors, insurance companies, and certain other prepetition creditors. As of the filing of these Schedules and SOFA, certain of those liabilities remained unpaid. As such, they may be listed on Schedule F.

The claims of individual creditors for, among other things, goods, services, or taxes listed on the Debtor's books and records may not reflect credits or allowances due from such creditors. The Debtor reserves all of its rights in

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 8 of 42

respect of such credits or allowances. The dollar amounts listed may be exclusive of contingent or unliquidated amounts.

Schedule F-1: Accounts Payable

Schedule F-1 contains a list of all of the Debtor's accounts payable as of the Commencement Date based on downloads from the accounts payable systems just prior to the final completion of the Schedules. If the amount owed to a creditor results in a net negative balance, such creditor is excluded from this Schedule.

Albemarle Corporation, an unsecured creditor listed on Schedule F-1, has asserted a demand to reclaim goods delivered to the Debtor within the forty-five (45) days prior to the Commencement Date. The asserted value of such goods is \$2,715,597.50. Albemarle's demand to reclaim such goods is unresolved as of the date of the filing these Schedules.

Schedule F-2: Litigation Claims

Schedule F-2 contains information regarding potential and pending litigation involving the Debtor. To the extent that litigation involving the Debtor has been identified, such information is contained on Schedule F-2.

Detailed information with respect to the pending lawsuit in which the Debtor is a defendant is provided in the response to SOFA Question 4. The plaintiff in such litigation is listed as a creditor on Schedule F-2. The amount of the liability with respect thereto is listed as "unliquidated" and marked as contingent, unliquidated, and disputed.

Schedule G – Executory Contracts and Unexpired Leases.

While the Debtor's existing books, records, and financial systems have been relied upon to identify and schedule executory contracts and unexpired leases, and although commercially reasonable efforts have been made to ensure the accuracy of Schedule G, inadvertent errors, omissions, or over inclusion may have occurred. The Debtor does not make, and specifically disclaims, any representation or warranty as to the completeness or accuracy of the information set forth on Schedule G. The Debtor hereby reserves all of its rights to dispute the validity, status, or enforceability of any contract, agreement, or lease set forth on Schedule G and to amend or supplement Schedule G as necessary. The contracts, agreements, and leases listed on Schedule G may have expired or may have been modified, amended, or supplemented from time to time by various amendments, restatements, waivers, estoppel certificates, letters, memoranda, and other documents, instruments, and agreements that may not be listed therein despite the Debtor's use of reasonable efforts to identify such documents. Further, unless otherwise specified on Schedule G, each executory contract or unexpired lease listed therein shall include all exhibits, schedules, riders, modifications, declarations, amendments, supplements, attachments, restatements, or other agreements made directly or indirectly by any agreement, instrument, or other document that in any manner affects such executory contract or unexpired lease, without regard to whether such agreement, instrument, or other document is listed thereon.

In some cases, the same supplier or provider appears multiple times on Schedule G. This multiple listing is intended to reflect distinct agreements between the Debtor and such supplier or provider.

In the ordinary course of business, the Debtor may have issued numerous purchase orders for services, supplies, product, and related items which, to the extent that such purchase orders constitute executory contracts, are not listed individually on Schedule G. To the extent that goods were delivered under purchase orders prior to the Commencement Date, vendors' claims with respect to such delivered goods are included on Schedule F.

As a general matter, certain of the Debtor's executory contracts and unexpired leases could be included in more than one category. In those instances, one category has been chosen to avoid duplication. Further, the designation of a category is not meant to be wholly inclusive or descriptive of the entirety of the rights or obligations represented by such contract.

Certain of the executory contracts and unexpired leases listed on Schedule G may contain certain renewal options, guarantees of payment, options to purchase, rights of first refusal, right to lease additional space, and other miscellaneous rights. Such rights, powers, duties, and obligations are not set forth separately on Schedule G.

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 9 of 42

In addition, the Debtor may have entered into various other types of agreements in the ordinary course of its business, such as indemnity agreements, supplemental agreements, amendments/letter agreements, title agreements, and confidentiality agreements. Such documents also are not set forth on Schedule G.

The Debtor hereby reserves all of its rights, claims, and causes of action with respect to the contracts and agreements listed on Schedule G, including the right to dispute or challenge the characterization or the structure of any transaction, document, or instrument related to a creditor's claim, to dispute the validity, status, or enforceability of any contract, agreement, or lease set forth on Schedule G, and to amend or supplement Schedule G as necessary. Inclusion of any agreement on Schedule G does not constitute an admission that such agreement is an executory contract within the meaning of section 365 of the Bankruptcy Code or unexpired lease, and the Debtor reserves all rights in that regard, including, without limitation, that any agreement is not executory, has expired pursuant to its terms, or was terminated prepetition. Omission of a contract or lease from Schedule G does not constitute an admission that the contract or lease is not an executory contract or unexpired lease.

In addition, certain of the agreements listed on Schedule G may be in the nature of secured financings. The presence of a contract or agreement on Schedule G does not constitute an admission that such contract or agreement is an executory contract or unexpired lease. The Debtor reserves all of its rights, claims, and causes of action with respect to the contracts and agreements listed on Schedule G, including the right to dispute or challenge the characterization or the structure of any transaction, or any document or instrument (including, without limitation, any intercreditor or intercompany agreement) related to a creditor's claim.

In the ordinary course of business, the Debtor has entered into numerous contracts or agreements, both written and oral, regarding the provision of certain services on a month to month basis. To the extent such contracts or agreements constitute executory contracts, these contracts and agreements are not listed individually on Schedule G.

Certain of the executory contracts may not have been memorialized and could be subject to dispute. Moreover, executory agreements that are oral in nature have not been included on Schedule G.

In the ordinary course of business, the Debtor has entered into confidentiality agreements which govern the disclosure and/or receipt of confidential information between the Debtor and outside companies, institutions, and individuals. There are no financial obligations associated with these types of agreements. To the extent that such confidentiality agreements constitute executory contracts, they are not listed individually on Schedule G.

The Debtor is a party to certain material transfer agreements with various third-party organizations (typically universities or other nonprofit entities). These organizations use the materials for research purposes, and there are no financial obligations between the Debtor and these counterparties. Additionally, the amount of materials transferred is negligible and has no assigned value.

The Debtor has used reasonable best efforts to list all executory contracts and unexpired leases under the correct agreement category. However, certain of the executory contracts and unexpired leases may be listed under the incorrect agreement category.

In addition, Schedule G does not include rejection damage claims of the counterparties to the executory contracts and unexpired leases that have been or may be rejected to the extent such damage claims exist.

SPECIFIC NOTES WITH RESPECT TO DEBTOR'S SOFA:

<u>SOFA – Question 2 – Income Other Than From Operations.</u> Non-operating income reported includes minimal amounts of interest from investment accounts and credit card reward refunds.

<u>SOFA – Question 3(b) – Ninety-Day Payments.</u> The dates set forth in the "Date of Payment" column relate to one of the following: (a) the date of a wire transfer; (b) the date of an "ACH" payment; or (c) the mailing date for a check or money order. Payments that were mailed in the ninety-day period but not presented have been excluded. Also, payments that were mailed outside of the ninety-day period, but were presented within the period, have been included. In addition to the payments disclosed in response to this Question, the Debtor

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 10 of 42

engaged in numerous transactions, including paying employee compensation and other employee obligations that the Debtor may not have included in response to this Question.

<u>SOFA – Question 3(c) – One-Year Payments.</u> Executive compensation reported includes value derived from salary, bonus, restricted stock, and option awards. Because of confidentiality concerns, payments made to members of the Board of Directors are shown as an aggregate amount, inclusive of fees and restricted stock units. Value was assigned to certain non-cash items, such as restricted stock units in accordance with the authoritative accounting literature based on the share price of the Debtor's common stock as of the grant date(s).

The Debtor leases its New York office space from MacAndrews & Forbes Group LLC, an affiliate of a significant shareholder of the Debtor. Question 3(c) lists monthly rent and related payments made to MacAndrews & Forbes Group LLC. The inclusion of MacAndrews & Forbes Group LLC herein is not intended to be, nor shall be, construed as a legal characterization of such party as an insider and does not act as an admission of any fact, claim, right, or defense, and all such rights, claims, and defenses are hereby expressly reserved.

<u>SOFA – Question 4 – Lawsuits.</u> The Debtor is not a plaintiff in any current lawsuits or any lawsuits within the one year immediately preceding the Commencement Date. SOFA Question 4 lists lawsuits where the Debtor is a defendant.

In the ordinary course of business, the Debtor may be obligated to withhold amounts from the paychecks of various employees in connection with garnishment orders or other state law withholding orders. The Debtor believes that these amounts do not constitute property of the estate and, accordingly, are not responsive to this Question. Moreover, out of concerns for the confidentiality of the Debtor's employees, the Debtor has not listed any such garnishment in response to this Question.

<u>SOFA – Question 7 – Gifts</u>. In the year preceding the Commencement Date, the Debtor made cash and other equipment contributions to the organizations listed in the response to this Question. While reasonable efforts have been made to ensure that the gifts listed in response to this Question include all gifts made, certain gifts inadvertently may have been omitted from the Schedules and SOFA.

<u>SOFA – Question 10 – Other Transfers.</u> The transfers of property listed here include all transfers by the Debtor that occurred outside the ordinary course of business.

In addition to the lab equipment that the Debtor sold, the Debtor sold/transferred a National Institute of Health grant for a research and development program of anti-arenavirus (Lassa fever) to Kineta Four LLC ("**Kineta**"). The Debtor transferred and assigned to Kineta the arenavirus know-how, patents, material, arenavirus documents and the Debtor's rights under the Lassa grant agreement on July 31, 2014. These assets held no book value to the Debtor. If, at some future date, Kineta develops a profitable product in connection with this grant, the Debtor will receive a share of cash distributions and royalties.

There may be various assets of de minimis value that were transferred or disposed of in the past two years. Those de minimis assets are also not listed in response to this Question.

<u>SOFA – Question 14 – Property Held for Another Person.</u> In the ordinary course of business, the Debtor utilizes various pieces of lab equipment that are owned by other parties.

<u>SOFA – Question 18 Nature and Location of Business.</u> The Debtor's response to Question 18 includes business interests acquired by the Debtor by merger or sold by the Debtor in the six years prior to the Commencement Date. SIGA Pharmaceuticals (Europe) LTD is an inactive entity with no operations or physical locations. The Debtor owns a 9.8% interest in Kineta Four LLC in the form of profit interest units. These units are nonvoting and had no book value as of the Commencement Date.

SOFA – Question 19(d) – Financial Statements Issued by the Debtor. Pursuant to the requirements of the Securities Exchange Act of 1934, at the end of each of its fiscal quarters and years and upon the occurrence of significant events, the Debtor prepares and files with the U.S. Securities and Exchange Commission (the "SEC") Form 10-Q Quarterly Reports, Form 10-K Annual Reports, and Form 8K Special Reports (collectively, the "SEC")

Entered 10/30/14 18:22:19 14-12623-shl Doc 112 Filed 10/30/14 Main Document

Pg 11 of 42 Filings"). The SEC Filings contain consolidated financial information relating to the Debtor. Additionally, the Debtor has historically provided information, such as annual reports, on its website. Because the SEC Filings and other reports are of public record, the Debtor does not maintain records of the parties who requested or obtained copies of any of the SEC Filings from the SEC, the Debtor, or other sources.

SOFA – Question 21(b) – Current Partners, Officers, Directors, and Shareholders. As of March 14, 2014 (reported on proxy), all executive officers and directors (including three former directors) owned an aggregate 2,903,628 shares of common stock of SIGA, representing 5.28% of common stock outstanding as of such date, including shares of common stock issuable upon exercise of options and stock-settled stock appreciation rights, but not including restricted stock units. No individual officer or director owns 5% or more of the common stock of SIGA.

The ownership interests provided in response to this Question for MacAndrews & Forbes Holdings, Inc. and Jet Capital Investors, LP are as of March 14, 2014 (reported on proxy) and June 30, 2014 (reported in SEC Form 13F), respectively.

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 12 of 42

B 6 Summary (Official Form 6 - Summary) (12/13)

United States Bankruptcy Court Southern District of New York

In re	SIGA Technologies, Inc.		Case No. 14-126	23 (SHL)	
	<u>-</u>	Debtor			
			Chapter	11	

SUMMARY OF SCHEDULES

Indicate as to each schedule whether that schedule is attached and state the number of pages in each. Report the totals from Schedules A, B, D, E, F, I, and J in the boxes provided. Add the amounts from Schedules A and B to determine the total amount of the debtor's assets. Add the amounts of all claims from Schedules D, E, and F to determine the total amount of the debtor's liabilities. Individual debtors must also complete the "Statistical Summary of Certain Liabilities and Related Data" if they file a case under chapter 7, 11, or 13.

NAME OF SCHEDULE	ATTACHED (YES/NO)	NO. OF SHEETS	ASSETS	LIABILITIES	OTHER
A - Real Property	Yes	1	0.00		
B - Personal Property	Yes	12	131,669,746.15		
C - Property Claimed as Exempt	No	0			
D - Creditors Holding Secured Claims	Yes	1		3,860,061.90	
E - Creditors Holding Unsecured Priority Claims (Total of Claims on Schedule E)	Yes	3		0.00	
F - Creditors Holding Unsecured Nonpriority Claims	Yes	6		4,094,583.50	
G - Executory Contracts and Unexpired Leases	Yes	4			
H - Codebtors	Yes	1			
I - Current Income of Individual Debtor(s)	No	0			N/A
J - Current Expenditures of Individual Debtor(s)	No	0			N/A
Total Number of Sheets of ALL Schedu	iles	28			
	To	otal Assets	131,669,746.15		
			Total Liabilities	7,954,645.40	

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 13 of 42

B6A (Official Form 6A) (12/07)

			a
In re	SIGA Technologies, Inc.		Case No. <u>14-12623 (SHL)</u>
_		······································	
		Debtor	

SCHEDULE A - REAL PROPERTY

Except as directed below, list all real property in which the debtor has any legal, equitable, or future interest, including all property owned as a cotenant, community property, or in which the debtor has a life estate. Include any property in which the debtor holds rights and powers exercisable for the debtor's own benefit. If the debtor is married, state whether husband, wife, both, or the marital community own the property by placing an "H," "W," "J," or "C" in the column labeled "Husband, Wife, Joint, or Community." If the debtor holds no interest in real property, write "None" under "Description and Location of Property."

Do not include interests in executory contracts and unexpired leases on this schedule. List them in Schedule G - Executory Contracts and Unexpired Leases.

If an entity claims to have a lien or hold a secured interest in any property, state the amount of the secured claim. See Schedule D. If no entity claims to hold a secured interest in the property, write "None" in the column labeled "Amount of Secured Claim." If the debtor is an individual or if a joint petition is filed, state the amount of any exemption claimed in the property only in Schedule C - Property Claimed as Exempt.

Description and Location of Property Nature of Debtor's Interest in Property	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption	Amount of Secured Claim
---	---	--	----------------------------

None

Sub-Total > 0.00 (Total of this page)

Total > **0.00**

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 14 of 42

B6B (Official Form 6B) (12/07)

In re	SIGA Technologies, Inc.		Case No	14-12623 (SHL)
_	,	Debtor		

SCHEDULE B - PERSONAL PROPERTY

Except as directed below, list all personal property of the debtor of whatever kind. If the debtor has no property in one or more of the categories, place an "x" in the appropriate position in the column labeled "None." If additional space is needed in any category, attach a separate sheet properly identified with the case name, case number, and the number of the category. If the debtor is married, state whether husband, wife, both, or the marital community own the property by placing an "H," "W," "J," or "C" in the column labeled "Husband, Wife, Joint, or Community." If the debtor is an individual or a joint petition is filed, state the amount of any exemptions claimed only in Schedule C - Property Claimed as Exempt.

Do not list interests in executory contracts and unexpired leases on this schedule. List them in Schedule G - Executory Contracts and Unexpired Leases.

If the property is being held for the debtor by someone else, state that person's name and address under "Description and Location of Property." If the property is being held for a minor child, simply state the child's initials and the name and address of the child's parent or guardian, such as "A.B., a minor child, by John Doe, guardian." Do not disclose the child's name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m).

	Type of Property	N O Description and Location of Property E	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption
1.	Cash on hand	Petty Cash - NY Office	-	335.68
2.	Checking, savings or other financial accounts, certificates of deposit, or shares in banks, savings and loan, thrift, building and loan, and homestead associations, or credit	Citibank - Operating Account Citibank CBO Services P O BOX 769018 San Antonio, TX 78245	-	79,353,432.37
	unions, brokerage houses, or cooperatives.	Citibank - Payroll Account Citibank CBO Services P O BOX 769018 San Antonio, TX 78245	-	13,829.25
		Citibank - Deposit Account Citibank CBO Services P O BOX 769018 San Antonio, TX 78245	-	29,378,214.94
		Citi Personal Wealth Management Investment Account 111 Wall Street 3rd Floor New York, NY 10043	-	99,930.00
		Chase Bank Disbursement (Checking) Account P O BOX 659754 San Antonio, TX 78265	-	2,925.88
3.	Security deposits with public utilities, telephone companies, landlords, and others.	TriNet Group, Inc. 1100 San Leandro Blvd. Suite 400 San Leandro, CA 94577	-	254,036.76
		Karex Property Management - Security Deposit for Corvallis Lease 45757 SW Research Way Ste 230 Corvallis OR 97333-1299	-	23,418.00

Sub-Total > **109,126,122.88** (Total of this page)

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 15 of 42

B6B (Official Form 6B) (12/07) - Cont.

In re	SIGA Technologies, Inc.	Case No. 14-12623 (SHL)	
	•		-

Debtor

SCHEDULE B - PERSONAL PROPERTY

	Type of Property	N O Description and Location of Property E	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption
		MacAndrews & Forbes Group, LLC - Security Deposit for New York Lease 660 Madison Ave. Suite 1700 New York, NY 10065	-	364,109.04
1.	Household goods and furnishings, including audio, video, and computer equipment.	X		
5.	Books, pictures and other art objects, antiques, stamp, coin, record, tape, compact disc, and other collections or collectibles.	X		
5.	Wearing apparel.	x		
7.	Furs and jewelry.	х		
3.	Firearms and sports, photographic, and other hobby equipment.	х		
€.	Interests in insurance policies. Name insurance company of each policy and itemize surrender or refund value of each.	X		
10.	Annuities. Itemize and name each issuer.	x		
11.	Interests in an education IRA as defined in 26 U.S.C. § 530(b)(1) or under a qualified State tuition plan as defined in 26 U.S.C. § 529(b)(1). Give particulars. (File separately the record(s) of any such interest(s). 11 U.S.C. § 521(c).)	X		
12.	Interests in IRA, ERISA, Keogh, or other pension or profit sharing plans. Give particulars.	x		
13.	Stock and interests in incorporated and unincorporated businesses. Itemize.	9.76% of profit interest units in Kineta Four, LLC Washington State	. <u>-</u>	Unliquidated
	ACIMZC.	100% ownership in SIGA Pharmaceuticals (Europ LTD	e) -	Unliquidated
14.	Interests in partnerships or joint ventures. Itemize.	X		
		(То	Sub-Tot tal of this page)	al > 364,109.04

Sheet <u>1</u> of <u>4</u> continuation sheets attached to the Schedule of Personal Property

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 16 of 42

B6B (Official Form 6B) (12/07) - Cont.

In re	SIGA	Technol	oaies.	Inc.
111 10	0.0/1		og.cc,	

Case No. 14-12623 (SHL)

Debtor

SCHEDULE B - PERSONAL PROPERTY

(Continuation Sheet)

			(Continuation Sheet)		
	Type of Property	N O N E	Description and Location of Property	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption
15.	Government and corporate bonds and other negotiable and nonnegotiable instruments.	х			
16.	Accounts receivable.		Accounts receivable balance as of 8/31/14	-	1,090,001.88
17.	Alimony, maintenance, support, and property settlements to which the debtor is or may be entitled. Give particulars.	X			
18.	Other liquidated debts owed to debtor including tax refunds. Give particulars.		Federal income tax refund - Internal Revenue Service	-	421,182.00
			State of California income tax refund - California Franchise Tax Board	-	800.00
			New Jersey income tax refund - New Jersey Corporation Business Tax Refund	-	7,517.00
			New York State income tax refund - NYS Department of Taxation	-	1,582.00
			Oregon income tax refund - Oregon Corporation Excise Tax	-	10,950.00
			New York City income tax refund - NYC Department of Finance	-	42,483.00
19.	Equitable or future interests, life estates, and rights or powers exercisable for the benefit of the debtor other than those listed in Schedule A - Real Property.	X			
20.	Contingent and noncontingent interests in estate of a decedent, death benefit plan, life insurance policy, or trust.	X			
21.	Other contingent and unliquidated claims of every nature, including tax refunds, counterclaims of the debtor, and rights to setoff claims. Give estimated value of each.	X			
22.	Patents, copyrights, and other intellectual property. Give particulars.		See Schedule B22 attachment	-	Unliquidated

Sub-Total > **1,574,515.88** (Total of this page)

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 17 of 42

B6B (Official Form 6B) (12/07) - Cont.

In re	SIGA Technologies, Inc.	Case No. 14-12623 (SHL)
_		,

Debtor

SCHEDULE B - PERSONAL PROPERTY (Continuation Sheet)

	Type of Property	N O N E	Description and Location of Property	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption
23.	Licenses, franchises, and other general intangibles. Give particulars.		State of Oregon, Department of Health and Human Services. Radioactive materials license number OR-90876 for 4575 SW Research Way, Suite 230 Corvallis, OR 97333	-	Unliquidated
			State of Washington, Department of Health. Site use permit number G2158 for low-level commercial radioactive waste disposal site in Washington.	-	Unliquidated
			State of Oregon, Department of Consumer and Business Services. Boiler permit 106472 - Autoclave located at 4575 SW Research Way, Suite 230 Corvallis, OR 97333	-	Unliquidated
			State of Oregon, Department of Consumer and Business Services. Boiler permit 109025- Bulk nitrogen tank located at 4575 SW Research Way, Suite 230 Corvallis, OR 97333	-	Unliquidated
			National Institutes of Health, Office of Technology Transfer. License L-055-2008/1 for Generation of Wild-Type Dengue Viruses	-	Unliquidated
			Oregon Secretary of State 136 State Capitol Salem, OR 97310-0722. Research and Development Certficiat of Validatio License ORE-90876 01	-	Unliquidated
			City of Corvallis. Alarm Permit 2235	-	Unliquidated
24.	Customer lists or other compilations containing personally identifiable information (as defined in 11 U.S.C. § 101(41A)) provided to the debtor by individuals in connection with obtaining a product or service from the debtor primarily for personal, family, or household purposes.	Х			
25.	Automobiles, trucks, trailers, and other vehicles and accessories.	X			
26.	Boats, motors, and accessories.	X			
27.	Aircraft and accessories.	X			
			(Total	Sub-Tota of this page)	al > 0.00

Sheet <u>3</u> of <u>4</u> continuation sheets attached to the Schedule of Personal Property

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 18 of 42

B6B (Official Form 6B) (12/07) - Cont.

In re	SIGA Technologies, Inc.	Case No. 14-12623 (SHL)
	<u> </u>	

Debtor

SCHEDULE B - PERSONAL PROPERTY

(Continuation Sheet)

	Type of Property	N O N E	Description and Location of Property	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption
28.	Office equipment, furnishings, and		Computer equipment - NY and Corvallis	-	194,178.00
	supplies.		Furniture and Fixtures - NY and Corvallis	-	169,409.00
			Leasehold improvements - NY and Corvallis	-	531,504.00
29.	Machinery, fixtures, equipment, and supplies used in business.		Corvallis office and lab construction	-	46,128.00
30.	Inventory.		Work-in-progress Inventory - Quakertown, Pennsylvania	-	2,715,598.00
			Work in-progress Inventory - Winchester, Kentucky	-	14,908,460.00
31.	Animals.	X			
32.	Crops - growing or harvested. Give particulars.	X			
33.	Farming equipment and implements.	X			
34.	Farm supplies, chemicals, and feed.	X			
35.	Other personal property of any kind not already listed. Itemize.		Westchester Fire Insurance Company - Bond (PharmAthene, Inc.)	-	1,347,956.00
			Prepaid Insurance	-	275,943.10
			Other Prepaid Expenses	-	250,822.25
			Prepaid Retainers	-	165,000.00

Sub-Total > 20,604,998.35

Total > 131,669,746.15

(Total of this page)

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case NC 94 12/2 of 42

					Current Value of Debtor's Interest in Property, Without Deducting Any
Type of Intellectual Property	Description of Property	Country or Organization	Application No.	Status	Secured Claim or Exemption
Patent	AMORPHOUS TECOVIRIMAT PREPARATION	World Intellectual Property Organization (WIPO)	PCT/US14/46340	Pending	Unliquidated
Patent	ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION	European Patent Office	8769679.5	Pending	Unliquidated
Patent	ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION	United States	12/601,187	Issued	Unliquidated
Patent	ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION	Vietnam	1-2009-02409	Pending	Unliquidated
Patent	ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION	United States	13/947,630	Pending	Unliquidated
Patent	CHEMICALS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	United States	11/785,998	Issued	Unliquidated
Patent	CHEMICALS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	Canada	2,685,153	Pending	Unliquidated
Patent	CHEMICALS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	China	200780053386	Pending	Unliquidated
Patent	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	United States	10/561,153	Issued	Unliquidated
Patent	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	Australia	2004249250	Issued	Unliquidated
Patent	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	Canada	2,529,761	Issued	Unliquidated
Patent	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	European Patent Office	4776765.2	Pending	Unliquidated
Patent	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	Japan	2006-517409	Issued	Unliquidated
	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS	Australia			
Patent	INFECTIONS AND ASSOCIATED DISEASES		2007351866	Issued	Unliquidated

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case No. 94-220-01 42

Time of letallestical Decrease.	Description of Superarty	Country on Opposite tier	Application No.	Chahara	Current Value of Debtor's Interest in Property, Without Deducting Any
Type of Intellectual Property	Description of Property	Country or Organization	Application No.	Status	Secured Claim or Exemption
Patent	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	European Patent Office	7755857.5	Pending	Unliquidated
Patent	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	Israel	201736	Pending	Unliquidated
ratent	INTECTIONS AND ASSOCIATED DISEASES		201730	rending	Omiquidated
	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS	Mexico			
Patent	INFECTIONS AND ASSOCIATED DISEASES		MX/a/2009/011533	Pending	Unliquidated
	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS	United States			
Patent	INFECTIONS AND ASSOCIATED DISEASES		11/785,997	Issued	Unliquidated
Dataset	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS	United States	42/542.544	lance d	Unitarridadad
Patent	INFECTIONS AND ASSOCIATED DISEASES		12/643,641	Issued	Unliquidated
Datast	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	United States	12/752,462	Issued	Unliquidated
Patent	INFECTIONS AND ASSOCIATED DISEASES		12/752,462	issueu	Offiliquidated
	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS	United States	40/404-407		
Patent	INFECTIONS AND ASSOCIATED DISEASES		13/194,437	Issued	Unliquidated
Patent	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	Japan	2011-179109	Pending	Unliquidated
	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS	Australia			
Patent	INFECTIONS AND ASSOCIATED DISEASES		2012268859	Pending	Unliquidated
Patent	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES	United States	13/966,392	Issued	Unliquidated
i attiti	INTECTIONS AND ASSOCIATED DISEASES		13/300,332	issucu	Omiquidated
Datast	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS	United States	44/222 507	David	III Carried
Patent	INFECTIONS AND ASSOCIATED DISEASES		14/323,587	Pending	Unliquidated
Patent	INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS	United States	13/578,413	Pending	Unliquidated

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case NC 94 222 of 42

Type of Intellectual Property	Description of Property	Country or Organization	Application No.	Status	Current Value of Debtor's Interest in Property, Without Deducting Any Secured Claim or Exemption
Type of intellectual Property	INHIBITORS AND METHODS OF INHIBITING BACTERIAL	Country of Organization	Application No.	Status	Secured Claim of Exemption
Patent	AND VIRAL PATHOGENS	European Patent Office	11745286.2	Pending	Unliquidated
Patent	INHIBITORS OF DENGUE VIRUS	Israel	214825	Pending	Unliquidated
Patent	INHIBITORS OF DENGUE VIRUS	Asia/Pacific Region	AP/P/2011/005901	Pending	Unliquidated
Patent	INHIBITORS OF DENGUE VIRUS	Brazil	1005828-1	Pending	Unliquidated
Patent	INHIBITORS OF DENGUE VIRUS	South Korea	10-2011-7022169	Pending	Unliquidated
Patent	METHODS OF PREPARING TECOVIRIMAT	World Intellectual Property Organization (WIPO)	PCT/US13/54816	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF S-246	Argentina	20110102672	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Canada	2,793,533	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Australia	2011232551	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Mexico	MX/a/2012/010859	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	European Patent Office	11760126	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Hong Kong	13107138.3	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Japan	2013-501426	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	China	201180024589	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Israel	221991	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Asia/Pacific Region	AP/P/2012/006514	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	India	3206/KOLNP/2012	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Brazil	112012023743-8	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Peru	1623-2012	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Singapore	201207032-2	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	New Zealand	602578	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246	Russia	2012144818	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246 AND METHODS OF PREPARATION	United States	13/069,813	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246 AND METHODS OF PREPARATION	South Africa	2012/07141	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246 AND METHODS OF PREPARATION	African Intellectual Property Organization	1201200384	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246 AND METHODS OF PREPARATION	South Korea	10-2012-7027664	Pending	Unliquidated
Patent	POLYMORPHIC FORM OF ST-246 AND METHODS OF PREPARATION	Chile	2012-02621	Pending	Unliquidated
Patent	REHYDRATION OF MICRONIZATION TECOVIRIMAT MONOHYDRATE	United States	61/906,119	Pending	Unliquidated
Patent	SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION	United States	12/736,965	Pending	Unliquidated
Patent	SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION	European Patent Office	9759215.8	Pending	Unliquidated
Patent	SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION	Mexico	MX/a/2010/013269	Pending	Unliquidated

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case NC 94-222-01 42

SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVIOUND FOR FOR THE TREATMENT OR FOR						Current Value of Debtor's Interest in Property, Without Deducting Any
Patent OR PREVENTION OF DENDEU VINUS INFECTION Incide Inci	Type of Intellectual Property	Description of Property	Country or Organization	Application No.	Status	Secured Claim or Exemption
Patent OR PREVENTION OF DENDEU VINUS INFECTION Incide Inci			l.e.			
SMALL MOLECULE INHIBITORS FOR THE TREATMENT PATENT OR PREVENTION OF DENOLU VIRUS INFECTION SMALL MOLECULE INHIBITORS FOR THE TREATMENT PATENT PATENT OR PREVENTION OF DENOLU VIRUS INFECTION SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLU VIRUS INFECTION SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLU VIRUS INFECTION SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLU VIRUS INFECTION MENDED SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLU VIRUS INFECTION MENDED SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLU VIRUS INFECTION MENDED SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLU VIRUS INFECTION MENDED SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLU VIRUS INFECTION MENDED SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLU VIRUS INFECTION MENDED SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLU VIRUS INFECTION MENDED SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLU VIRUS INFECTION MENDED MENDED SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLUL VIRUS INFECTION MITCH STATES MENDED MENDED MENDED SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENOLUL VIRUS INFECTIONS MITCH SMALL MOLECULE MENDED MEND			vietnam			
Patent OR REVENTION OF DENGUE VIRUS INFECTION SMALL MOLECULE INHIBITORS FOR THE TREATMENT Israel Patent OR PREVENTION OF DENGUE VIRUS INFECTION SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION Patent OR PREVENTION OF DENGUE VIRUS INFECTION Patent OR PREVENTION OF DENGUE VIRUS INFECTION Patent ST-246 LIQUID FORMULATIONS AND METHODS United States 13/814.102 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS United States 13/814.102 Pending Uniquidated Virus ST-246 LIQUID FORMULATIONS AND METHODS United States 13/814.102 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807.258 Pending Uniquidated Virus ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807.258 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807.258 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807.258 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807.258 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS CANADA 2,807.258 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS HONG Kong 100.2013/7005710 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10.2013/7005710 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10.2013/7005730 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10.2013/7005730 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10.2013/7005730 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10.2013/7005730 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10.2013/7005730 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Korea 11.2013/7005730 Pending Uniquid	Patent	OR PREVENTION OF DENGUE VIRUS INFECTION		1-2010-03238	Pending	Unliquidated
Patent OR PREVENTION OF DENGUE VIRUS INFECTION SAMAL MOLECULE INHIBITORS FOR THE TREATMENT Israel Patent OR PREVENTION OF PENGUE VIRUS INFECTION SAMAL MOLECULE INHIBITORS FOR THE TREATMENT ISRAEL SAMAL MOLECULE INHIBITORS FOR THE TREATMENT IN HONG KONG SAMAL MOLECULE INHIBITORS FOR THE TREATMENT IN HONG KONG Patent OR PREVENTION OF DENGUE VIRUS INFECTION AND PATENT OR PREVENTION OF DENGUE VIRUS INFECTION Patent OR PREVENTION OF DENGUE VIRUS INFECTION A REPORT OF THE TREATMENT OR THE TREATMENT IN HONG KONG Patent ST-246 LIQUID FORMULATIONS AND METHODS UNITED AUGUST OF THE TREATMENT OR		SMALL MOLECULE INHIBITORS FOR THE TREATMENT	India			
SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGLE VIRUS INFECTION SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGLE VIRUS INFECTION Patient OR PREVENTION OF DENGLE VIRUS INFECTION Patient ST-246 LIQUID FORMULATIONS AND METHODS Appenting OF DER	Datant		liidia	9102/DELND/2010	Donding	Unliquidated
Patent OR PREVENTION OF DENGUE VIRUS INFECTION SMALL MOLECULE INHIBITORS FOR THE TREATMENT HONG KONG Prevention OR PREVENTION OF DENGUE VIRUS INFECTION 11108398.8 Patent ST-246 LIQUID FORMULATIONS AND METHODS Argentina 20110102829 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Australia 20110102829 Pending Unilquidated Varient ST-246 LIQUID FORMULATIONS AND METHODS Australia 20110102829 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Australia 20110102829 Pending Unilquidated Varient ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807,528 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Consider Varient ST-246 LIQUID FORMULATIONS AND METHODS European Patent Office 201180048043.1 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS European Patent Office 201180048043.1 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS European Patent Office 201180048043.1 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Japan 2013-532271 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Japan 2013-532271 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Japan 2013-532271 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico MAY/2013/001389 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico MAY/2013/001389 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 2018/002900 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 2018/002900 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 2018/002900 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 2018/002900 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 2018/002900 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 2018/002900 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 2018/002900 Pending Unilquidated Patent S	ratent	OR PREVENTION OF DENGGE VIROS INFECTION		8193/DELNP/2010	Penang	Omiquidated
Patent OR PREVENTION OF DENGUE VIRUS INFECTION SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PROFESSION OR PROMISE OF THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION 11108398.8 Patent ST-246 LIQUID FORMULATIONS AND METHODS Argentina 2011012829 Pending Unilquidated Tabent ST-246 LIQUID FORMULATIONS AND METHODS United States 13/814,102 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Australia 20110188871 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807,528 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Consider the ST-246 LIQUID FORMULATIONS AND METHODS Consider the ST-246 LIQUID FORMULATIONS AND METHODS European Patent ST-246 LIQUID FORMULATIONS AND METHODS European Patent Office 201180048043.1 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS European Patent Office 201180048043.1 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Indigen ST-246 LIQUID FORMULATIONS AND METHODS Japan 2013-523271 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Japan 2013-523271 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Japan 2013-523271 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico MA/a/2013/001389 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico MA/a/2013/001389 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico MA/a/2013/001389 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLMP/2013 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLMP/2013 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLMP/2013 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLMP/2013 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLMP/2013 Pending Unilquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLMP/2013 Pending Unilquidated Pending Unilquidated Patent AND PR		SMALL MOLECULE INHIBITORS FOR THE TREATMENT	Israel			
Patent OR PREVENTION OF DENGLE VIRUS INFECTION Argentina 2011002829 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Argentina 2011002829 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Australia 2011285871 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Australia 2011285871 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Australia 2011285871 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807,528 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS China 201180048043.1 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS China 201180048043.1 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong 13112094 S Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong 13112094 S Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong 13112094 S Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS S Dapan 2013-522271 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS SOuth Korea 10-2013-7005710 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS SOUTH Korea 10-2013-7005710 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico MX/x/2013/001389 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS SOUTH Africa 2013/00930 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS SOUTH Africa 2013/00930 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS SOUTH Africa 2013/00930 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS SOUTH Africa 2013/00930 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS SOUTH Africa 2013/00930 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS SOUTH Africa 2013/00930 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS SOUTH Africa 2013/00930 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS SOUTH Africa 2013/00930 Pending Uniquidated Patent ST-246	Patent			209380	Pending	Unliquidated
Patent OP PREVENTION OF DENGUE VIRUS INFECTION Patent ST-246 LQUID FORMULATIONS AND METHODS Argentina 2011012829 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Australia 2011028271 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Australia 2011285871 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Canada 2, 2,807,528 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Canada 2, 2,807,528 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS China 201180048043.1 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS China 201180048043.1 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS South Kore 102-013-7005710 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS South Kore 102-013-7005710 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS South Africa Patent ST-246 LQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Singapore 2013007000-0 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Singapore 2013007000-0 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Singapore 2013007000-0 Pending Unilquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Singapore 2013007000-0 Pending Unilquidated Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 13/203,351 Pending Unilquidated Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unilquidated Unilquidated Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2014 Africa 2010128152 Pending Unilqui	i diciii	ONT REVENTION OF BENGGE VINGS IN ECTION		203300	renang	Ormquidated
Patent OR PREVENTION OF DENGUE VIRUS INFECTION Patent ST-246 LQUID FORMULATIONS AND METHODS Argentina 20110102829 Pending Uniquidated Patent ST-246 LQUID FORMULATIONS AND METHODS United States 13/814,102 Pending Uniquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Australia 2011285871 Pending Uniquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Canada 2,807,528 Pending Uniquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Canada 2,807,528 Pending Uniquidated Patent ST-246 LQUID FORMULATIONS AND METHODS China 201180048043.1 Pending Uniquidated ST-246 LQUID FORMULATIONS AND METHODS China 201180048043.1 Pending Uniquidated Patent ST-246 LQUID FORMULATIONS AND METHODS China 201180048043.1 Pending Uniquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Uniquidated Patent ST-246 LQUID FORMULATIONS AND METHODS Is appared to the state of ST-246 LQUID FORMULATIONS AND METHODS SHORE STATE ST-246 LQUID FORMULATIONS AND METHODS SHORE STATE S		SMALL MOLECULE INHIBITORS FOR THE TREATMENT	Hong Kong		Pending	Unliquidated
Patent ST-266 LIQUID FORMULATIONS AND METHODS United States 13/814,102 Pending Uniquidated ST-266 LIQUID FORMULATIONS AND METHODS Abustralia 2011285871 Pending Uniquidated Patent ST-266 LIQUID FORMULATIONS AND METHODS Abustralia 2011285871 Pending Uniquidated ST-266 LIQUID FORMULATIONS AND METHODS Canada 2,807,528 Pending Uniquidated Patent ST-266 LIQUID FORMULATIONS AND METHODS China 2,1807,528 Pending Uniquidated Patent ST-266 LIQUID FORMULATIONS AND METHODS China 2,1807,528 Pending Uniquidated ST-266 LIQUID FORMULATIONS AND METHODS China 2,1807,528 Pending Uniquidated ST-266 LIQUID FORMULATIONS AND METHODS European Patent Office 201180048043.1 Pending Uniquidated Patent ST-266 LIQUID FORMULATIONS AND METHODS Hong Kong Patent ST-266 LIQUID FORMULATIONS AND METHODS Japan 2013-523271 Pending Uniquidated Patent ST-266 LIQUID FORMULATIONS AND METHODS South Korea 10-2013-7005710 Pending Uniquidated Patent ST-266 LIQUID FORMULATIONS AND METHODS Mexico My/3/2013/001389 Pending Uniquidated Patent ST-266 LIQUID FORMULATIONS AND METHODS Mexico My/3/2013/001389 Pending Uniquidated State Uniquidated ST-266 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Uniquidated State Uniquidated ST-266 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Uniquidated State Uniquidated ST-266 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Uniquidated State Uniquidated ST-266 LIQUID FORMULATIONS AND METHODS Singapore 201300700-0 Pending Uniquidated State Uniquidated ST-266 LIQUID FORMULATIONS AND METHODS Singapore 201300700-0 Pending Uniquidated State Uniquidated ST-266 LIQUID FORMULATIONS AND METHODS Singapore 201300700-0 Pending Uniquidated States Pending Uniquidated States Pending Uniquidated States Pending Uniquidated Thinopyripine Derivatives For the Treatment AND PREVENTION OF DENGUE VIRUS INFECTIONS 2016 States Pending Uniquidated Pending Uniquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2016 States Pending Uniquidated Uniquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2016 State	Patent		gg	11108398 8	. c.i.a.i.g	oquiauteu
Patent ST-246 LIQUID FORMULATIONS AND METHODS Australia 2011285871 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807,528 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807,528 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807,528 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS China 201180048043.1 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS European Patent Office Patent ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Apparent ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10-2013-7005710 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10-2013-7005710 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico M/4/2/013/001389 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Mexico M/4/2/013/001389 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Brazil 112013002646-4 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Brazil 112013002646-4 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated ST-246 LIQUID FORMULAT			Argentina		Pending	Unliquidated
Patent ST-246 LIQUID FORMULATIONS AND METHODS Canada 2,807,528 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Chanda 2,807,528 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Chanda 201180048043.1 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS European Patent Office 201180048043.1 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10-2013-7005710 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Korea ST-246 LIQUID FORMULATIONS AND METHODS South Korea ST-246 LIQUID FORMULATIONS AND METHODS South Korea ST-246 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS SIZE SIZE SIZE SIZE SIZE SIZE SIZE SIZ						·
Patent ST-246 LIQUID FORMULATIONS AND METHODS European Patent Office 201180048043.1 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Japan 2013-523271 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS SOUth Korea 10-2013-7005710 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Mexico MK/a/2013/001389 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico MK/a/2013/00390 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Brazil 12013/00930 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Brazil 12013/00930 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Brazil 12013/00930 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Brazil 12013/00930 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Ingapore 2013/00700-0 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Ingapore 2013/00700-0 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 224431 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 13/203,351 Pending Unliquidated Unliquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2012/18152 Pending Unliquidated Unliquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2014/06270 Pending Unliquidated Unliquidated Unliquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2014/06270 Pending Unliquidated Unliquidated Unliquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2014/06270 Pending Unliquidated Unliquidated Unliqu		ST-246 LIQUID FORMULATIONS AND METHODS				·
Patent ST-246 LIQUID FORMULATIONS AND METHODS China 20180048043.1 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Uniquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Hong Kong 13112094.5 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS South Kora 10-2013-523271 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS South Kora 10-2013-523271 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS Mexico MK/a/2013/001389 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS Mexico MK/a/2013/001389 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS Brazil 1120/300246-4 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS Singapore 2013/00700-0 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2011 Pending Uniquidated Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2011 Pending Uniquidated Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2011 Pending Uniquidated Uniquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2011 Pending Uniquidated Uniquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 13/4012 Pending Uniquidated Uniquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2018-153,421 Pending Uniquidated Uniquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2018-153,421 Pending Uniquidated Uniquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2018-153,421 Pending Uniquidated Uniquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2018-153,421 Pending Uniquidated Uniquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2018-153,421 Pending Uniquidated Uniquidated AND PRE	Patent	ST-246 LIQUID FORMULATIONS AND METHODS	Canada	2,807,528	Pending	Unliquidated
Patent ST-266 LIQUID FORMULATIONS AND METHODS European Patent Office 201180048043.1 Pending Unliquidated Unliquidated 13112094.5 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 201300700-0 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 201300700-0 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Unliquidated Pending Unliquidated Pending Unliquidated Unliquidated Pending Unliquidated Pending Unliquidated Pending Unliquidated Unliquidated Pending Unliquidated Pending Unliquidated Pending Unliquidated Pending Unliquidated Pending Unliquidated Unliquidated Pending Unliq		ST-246 LIQUID FORMULATIONS AND METHODS				·
Patent ST-246 LIQUID FORMULATIONS AND METHODS Japan 2013-523271 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10-2013-7005710 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico MX/a/2013/001389 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Brazil 112013002646-4 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Brazil 112013002646-4 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT India Pending Unliquidated Patent AND PREVENTION OF DENDGUE VIRUS INFECTIONS 7358/DELNP/2011 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated Unliquidated	Patent	ST-246 LIQUID FORMULATIONS AND METHODS	European Patent Office	201180048043.1		Unliquidated
Patent ST-246 LIQUID FORMULATIONS AND METHODS Japan 2013-523271 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Korea 10-2013-7005710 Pending Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Mexico MX/a/2013/001389 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Brazil 112013002646-4 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Brazil 112013002646-4 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 201300700-0 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT India Pending Unliquidated Patent AND PREVENTION OF DENDGUE VIRUS INFECTIONS 7358/DELNP/2011 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT Australia AND PREVENTION OF DENGGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated Unliquidated Unliquidated Unliquidated Patent AND PREVENTION OF DENGGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated Unliquidated	Patent	ST-246 LIQUID FORMULATIONS AND METHODS	Hong Kong	13112094.5	Pending	Unliquidated
Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico MX/a/2013/001389 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Brazil 11201300266-4 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 201300700-0 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Target Street Str	Patent	ST-246 LIQUID FORMULATIONS AND METHODS		2013-523271		Unliquidated
Patent ST-246 LIQUID FORMULATIONS AND METHODS Mexico MX/a/2013/001389 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS South Africa 2013/00930 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Brazil 112013002646-4 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 201300700-0 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated Unliquidated Patent AND PREVENTION OF DENDGUE VIRUS INFECTIONS 7358/DELNP/2011 Pending Unliquidated Unliquidated Patent AND PREVENTION OF DENDGUE VIRUS INFECTIONS 13/203,351 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated Unliquidated Unliquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated Unliquidated Unliquidated Unliquidated AND PREVENTION OF DENGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated	Patent	ST-246 LIQUID FORMULATIONS AND METHODS	South Korea	10-2013-7005710	Pending	Unliquidated
Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 201300700-0 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Singapore 201300700-0 Pending Unliquidated Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Unliquidated ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENDGUE VIRUS INFECTIONS THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 13/203,351 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 13/203,351 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated U		ST-246 LIQUID FORMULATIONS AND METHODS	Mexico	MX/a/2013/001389		-
Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated Pending Unliquidated Patent AND PREVENTION OF DENDGUE VIRUS INFECTIONS THE TREATMENT AND PREVENTION OF DENDGUE VIRUS INFECTIONS 13/203,351 Pending Unliquidated Pending Unliquidated Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 13/203,351 Pending Unliquidated Pending Unliquidated Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 13/203,351 Pending Unliquidated Pending Unliquidated Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated Unliquidated Pending Unli	Patent	ST-246 LIQUID FORMULATIONS AND METHODS	South Africa	2013/00930	Pending	Unliquidated
Patent ST-246 LIQUID FORMULATIONS AND METHODS India 305/KOLNP/2013 Pending Unliquidated Patent ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENDGUE VIRUS INFECTIONS 7358/DELNP/2011 Patent AND PREVENTION OF DENGGUE VIRUS INFECTIONS 13/203,351 Pending Unliquidated Unliquidated Pending Unliquidated Pending Unliquidated Unliquidated Pending Unliquidated Unliquidated Unliquidated Pending Unliquidated Unliquidated Unliquidated Pending Unliquidated Unliquidated Pending Unliquidated Unliquidated Unliquidated Unliquidated Unliquidated Unliquidated Unliquidated Pending Unliquidated Unliquidated Unliquidated Unliquidated Unliquidated Unliquidated Pending Unliquidated Unliquidated Unliquidated Unliquidated Unliquidated Unliquidated Unliquidated Unliquidated Pending Unliquidated Unliquidat	Patent	ST-246 LIQUID FORMULATIONS AND METHODS	Brazil	112013002646-4	Pending	Unliquidated
Patent ST-246 LIQUID FORMULATIONS AND METHODS Israel 224431 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENDGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Australia Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS South Africa 2011/06270 Pending Unliquidated Unliquidated	Patent	ST-246 LIQUID FORMULATIONS AND METHODS	Singapore	201300700-0	Pending	Unliquidated
THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENDGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENDGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS South Africa Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS Pending Unliquidated Unliquidated	Patent	ST-246 LIQUID FORMULATIONS AND METHODS	India	305/KOLNP/2013	Pending	Unliquidated
Patent AND PREVENTION OF DENDGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Patent	ST-246 LIQUID FORMULATIONS AND METHODS	Israel	224431	Pending	Unliquidated
THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS Australia THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS AND PREVENTION OF DENGUE VIRUS INFECTIONS Patent THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Pending Unliquidated Unliquidated Unliquidated		THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT	India		Pending	Unliquidated
Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 13/203,351 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Petent AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS South Africa 2011/06270 Pending Unliquidated	Patent	AND PREVENTION OF DENDGUE VIRUS INFECTIONS		7358/DELNP/2011		
Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT Australia Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT Australia THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated						
THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Australia THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS South Africa Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated			United States		Pending	Unliquidated
Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated Unliquidated Unliquidated	Patent	AND PREVENTION OF DENGUE VIRUS INFECTIONS		13/203,351		
Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2,753,421 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated Unliquidated Unliquidated						
THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS South Africa Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS AUSTRALIA 2010218152 Pending Unliquidated Unliquidated			Canada	2 752 424	D 11	
Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated Unliquidated	Patent	AND PREVENTION OF DENGUE VIRUS INFECTIONS		2,753,421	Pending	Unliquidated
Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2010218152 Pending Unliquidated THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated Unliquidated		THIENODYDIDINE DEDIVATIVES FOR THE TREATMENT	Australia			
THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS South Africa 2011/06270 Pending Unliquidated	Detect		Australia	2010216152	Da . Jr	11a0. sa.c.a
Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated	Patent	AND PREVENTION OF DENGUE VIKUS INFECTIONS		2010218152	Penaing	Uniiquidated
Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS 2011/06270 Pending Unliquidated		THIENODYDIDINE DEDIVATIVES FOR THE TREATMENT	South Africa			
	Datant		South Affica	2011/06270	Dondina	Halianidatad
THEN OPPODING DEDIVATIVES FOR THE TREATMENT. Movies	rateilt	AND FREVENTION OF DENGUE VIRUS INFECTIONS		2011/002/0	renang	Omiquidated
		THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT	Mexico		Pending	Unliquidated
Patent AND PREVENTION OF DENGUE VIRUS INFECTIONS MX/a/2011/008988	Datent		IVICAICO	MV/2/2011/00000	reliuling	Omiquidated

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case NC 94.23 of 42

					Current Value of Debtor's Interest in Property, Without Deducting Any
Type of Intellectual Property	Description of Property	Country or Organization	Application No.	Status	Secured Claim or Exemption
Patent	THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	European Patent Office	10746743.3	Pending	Unliquidated
Patent	THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Japan	2011-552100	Pending	Unliquidated
Patent	THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	China	201080016715.6	Pending	Unliquidated
Patent	THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	African Intellectual Property Organization	1201100301	Issued	Unliquidated
Patent	THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Hong Kong	12104769.7	Pending	Unliquidated
Patent	THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	United States	13/708,224	Pending	Unliquidated
Patent	THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	World Intellectual Property Organization (WIPO)	PCT/US13/73449	Pending	Unliquidated
Patent	THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Japan	To be assigned	Pending	Unliquidated
Patent	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	United States	13/379,776	Pending	Unliquidated
Patent	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	European Patent Office	10794556	Pending	Unliquidated
Patent	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Hong Kong	12104770.4	Pending	Unliquidated
Patent	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	South Korea	10-2011-7030640	Pending	Unliquidated
Patent	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Mexico	MX/a/2011/012983	Pending	Unliquidated
Patent	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Israel	216605	Pending	Unliquidated
Trademark	ARESTVYR	Argentina	3220385	Pending	Unliquidated
Trademark	ARESTVYR	Australia	1534170	Registered	Unliquidated
Trademark	ARESTVYR	Brazil	840421036	Pending	Unliquidated
Trademark	ARESTVYR	Canada	1591579	Pending	Unliquidated
Trademark	ARESTVYR	European Patent Office	11151537	Registered	Unliquidated
Trademark	ARESTVYR	Hong Kong	302513673	Registered	Unliquidated
Trademark Trademark	ARESTVYR	India	2461796	Pending	Unliquidated
Trademark Trademark	ARESTVYR ARESTVYR	Israel	249100 012 - 73 ,753	Registered Registered	Unliquidated Unliquidated
Trademark Trademark	ARESTVYR	Japan Korea, Republic of	40-2012-57097	-	Unliquidated
Trademark	ARESTVYR	Mexico	1338017	Registered Registered	Unliquidated

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case N. 04.22/20 142

					Current Value of Debtor's Interest in
					Property, Without Deducting Any
Type of Intellectual Property	Description of Property	Country or Organization	Application No.	Status	Secured Claim or Exemption
rademark	ARESTVYR	Norway	201209177	Registered	Unliquidated
Frademark Trademark	ARESTVYR	Singapore	T1302286Z	Registered	Unliquidated
rademark	ARESTVYR	South Africa	2013/00861	Pending	Unliquidated
rademark	ARESTVYR	Switzerland	60261/2012	Registered	Unliquidated
Frademark	ARESTVYR	United States	85/568,516	Registered	Unliquidated
Frademark	ARESTVYR (Class 35)	China (People's Republic)	12154061	Pending	Unliquidated
Trademark	ARESTVYR (Class 5)	China (People's Republic)	12154060	Pending	Unliquidated
rademark	HUMAN BIOARMOR	United States	77/977,748	Registered	Unliquidated
rademark	SIGA	Argentina	2809653	Registered	Unliquidated
rademark	SIGA	Australia	1344770	Registered	Unliquidated
rademark	SIGA	Brazil	829690824	Pending	Unliquidated
Trademark	SIGA	Canada	1386919	Pending	Unliquidated
Frademark Trademark	SIGA	European Patent Office	6780811	Registered	Unliquidated
rademark	SIGA	Hong Kong	301073231	Registered	Unliquidated
rademark	SIGA	India	1665309	Registered	Unliquidated
rademark	SIGA	Israel	209494	Registered	Unliquidated
rademark	SIGA	Korea, Republic of	40-2008-14092	Registered	Unliquidated
rademark	SIGA	Pakistan	247875	Pending	Unliquidated
rademark	SIGA	Russian Federation	2008707332	Registered	Unliquidated
rademark	SIGA	Singapore	T0803130I	Registered	Unliquidated
rademark	SIGA	South Africa	2008/06387	Registered	Unliquidated
rademark	SIGA	Taiwan	97011593	Registered	Unliquidated
rademark	SIGA	United States	77/977,868	Registered	Unliquidated
rademark	SIGA	United States	77/977,750	Registered	Unliquidated
rademark	SIGA (AND DESIGN)	Australia	1343869	Registered	Unliquidated
rademark	SIGA (and Shield Design)	Saudi Arabia	175205	Registered	Unliquidated
rademark	SIGA (and Shield Design)	Saudi Arabia	175206	Registered	Unliquidated
rademark	SIGA (and Shield Design)	Taiwan	101005045	Registered	Unliquidated
rademark	SIGA (and Shield Design)	United States	77/977,869	Registered	Unliquidated
rademark	SIGA (and Shield Design)	United States	77/977,749	Registered	Unliquidated
rademark	SIGA TECHNOLOGIES	Japan	2014-61040	Pending	Unliquidated
rademark	ST-246	Argentina	2741401	Registered	Unliquidated
rademark	ST-246	Australia	1173683	Registered	Unliquidated
rademark	ST-246	Brazil	829136185	Registered	Unliquidated
rademark	ST-246	Canada	1673404	Pending	Unliquidated
rademark	ST-246	China (People's Republic)	6016347	Registered	Unliquidated
rademark	ST-246	European Patent Office	5942057	Registered	Unliquidated
rademark	ST-246	Hong Kong	300857287	Registered	Unliquidated
rademark	ST-246	India	1566447	Registered	Unliquidated
rademark	ST-246	Israel	199829	Registered	Unliquidated
rademark	ST-246	Korea, Republic of	40-2007-24640	Registered	Unliquidated
rademark	ST-246	Mexico	853405	Registered	Unliquidated
rademark	ST-246	Pakistan	236425	Pending	Unliquidated
rademark	ST-246	Saudi Arabia	117493	Registered	Unliquidated

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case NC 94.25 of 42

					Current Value of Debtor's Interest in
					Property, Without Deducting Any
Type of Intellectual Property	Description of Property	Country or Organization	Application No.	Status	Secured Claim or Exemption
Trademark	ST-246	Singapore	T07/09739Z	Registered	Unliquidated
Trademark	ST-246	South Africa	2007/10730	Pending	Unliquidated
Trademark	ST-246	United States	77/148,474	Registered	Unliquidated
Trademark	VARBLOCK	United States	85/568,561	Pending	Unliquidated

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 26 of 42

B6D (Official Form 6D) (12/07)

In re	SIGA Technologies, Inc.		Case No	14-12623 (SHL)	
_		Debtor			

SCHEDULE D - CREDITORS HOLDING SECURED CLAIMS

State the name, mailing address, including zip code, and last four digits of any account number of all entities holding claims secured by property of the debtor as of the date of filing of the petition. The complete account number of any account the debtor has with the creditor is useful to the trustee and the creditor and may be provided if the debtor chooses to do so. List creditors holding all types of secured interests such as judgment liens, garnishments, statutory liens, mortgages, deeds of trust, and other security interests.

other security interests.

List creditors in alphabetical order to the extent practicable. If a minor child is a creditor, the child's initials and the name and address of the child's parent or guardian, such as "A.B., a minor child, by John Doe, guardian." Do not disclose the child's name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m). If all secured creditors will not fit on this page, use the continuation sheet provided.

If any entity other than a spouse in a joint case may be jointly liable on a claim, place an "X" in the column labeled "Codebtor", include the entity on the appropriate schedule of creditors, and complete Schedule H - Codebtors. If a joint petition is filed, state whether the husband, wife, both of them, or the marital community may be liable on each claim by placing an "H", "W", "J", or "C" in the column labeled "Husband, Wife, Joint, or Community".

If the claim is contingent, place an "X" in the column labeled "Contingent". If the claim is unliquidated, place an "X" in the column labeled "Unliquidated". If the claim is disputed, place an "X" in the column labeled "Disputed". (You may need to place an "X" in more than one of these three columns.)

Total the columns labeled "Amount of Claim Without Deducting Value of Collateral" and "Unsecured Portion, if Any" in the boxes labeled "Total(s)" on the last sheet of the completed schedule. Report the total from the column labeled "Unsecured Portion" on the Statistical Summary of Schedules and, if the debtor is an individual with primarily consumer debts, report the total from the column labeled "Unsecured Portion" on the Statistical Summary of Certain Liabilities and Related Data.

Check this box if debtor has no creditors holding secured claims to report on this Schedule D.

Check this box if debtor has no creditors holding secured claims to report on this Schedule D.

	_	_		_				
CREDITOR'S NAME AND MAILING ADDRESS INCLUDING ZIP CODE, AND ACCOUNT NUMBER (See instructions above.)	C O D E B T O R	Hu H W J C	sband, Wife, Joint, or Community DATE CLAIM WAS INCURRED, NATURE OF LIEN, AND DESCRIPTION AND VALUE OF PROPERTY SUBJECT TO LIEN	CONTINGEN	LIQUIDA	I S P U T	AMOUNT OF CLAIM WITHOUT DEDUCTING VALUE OF COLLATERAL	UNSECURED PORTION, IF ANY
Account No.			Loan and Security Agreement - 12/31/12] ⊤	E D			
General Electric Capital Corporation Two Bethesda Metro Center Suite 600 Bethesda, MD 20814		_	Value \$ Unliquidated				2,512,105.90	Unliquidated
Account No.	t	\vdash	Bond (PharmAthene, Inc.) - 6/22/12	H		H	2,5 : 2, : 55:55	•
Westchester Fire Insurance Company 436 Walnut Street WA10G Philadelphia, PA 19106-3703		-		x		x		
			Value \$ Unliquidated				1,347,956.00	Unliquidated
Account No.	-		Value \$					
Account No.								
			Value \$					
continuation sheets attached			S (Total of th	ubt his			3,860,061.90	0.00
	Total (Report on Summary of Schedules)							0.00

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 27 of 42

B6E (Official Form 6E) (4/13)

In re	SIGA Technologies, Inc.		Case No. 14-12623 (SHL)
		Debtor,	•

SCHEDULE E - CREDITORS HOLDING UNSECURED PRIORITY CLAIMS

A complete list of claims entitled to priority, listed separately by type of priority, is to be set forth on the sheets provided. Only holders of unsecured claims entitled to priority should be listed in this schedule. In the boxes provided on the attached sheets, state the name, mailing address, including zip code, and last four digits of the account number, if any, of all entities holding priority claims against the debtor or the property of the debtor, as of the date of the filing of the petition. Use a separate continuation sheet for each type of priority and label each with the type of priority.

The complete account number of any account the debtor has with the creditor is useful to the trustee and the creditor and may be provided if the debtor chooses to do so. If a minor child is a creditor, state the child's initials and the name and address of the child's parent or guardian, such as "A.B., a minor child, by John Doe, guardian." Do not disclose the child's name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m).

If any entity other than a spouse in a joint case may be jointly liable on a claim, place an "X" in the column labeled "Codebtor," include the entity on the appropriate schedule of creditors, and complete Schedule H-Codebtors. If a joint petition is filed, state whether the husband, wife, both of them, or the marital community may be liable on each claim by placing an "H," "W," "J," or "C" in the column labeled "Husband, Wife, Joint, or Community." If the claim is contingent, place an "X" in the column labeled "Contingent." If the claim is unliquidated, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Unliquidated." If the claim is disputed the column labeled "Unliquidated." If the claim is disputed the column labeled "Unliquidated." If the claim is disputed the column labeled "Unliquidated." If the claim is dispute

"Disputed." (You may need to place an "X" in more than one of these three columns.) Report the total of claims listed on each sheet in the box labeled "Subtotals" on each sheet. Report the total of all claims listed on this Schedule E in the box "Total" on the last sheet of the completed schedule. Report this total also on the Summary of Schedules. Report the total of amounts entitled to priority listed on each sheet in the box labeled "Subtotals" on each sheet. Report the total of all amounts entitled to pr listed on this Schedule E in the box labeled "Totals" on the last sheet of the completed schedule. Individual debtors with primarily consumer debts report this total also on the Statistical Summary of Certain Liabilities and Related Data. Report the total of amounts not entitled to priority listed on each sheet in the box labeled "Subtotals" on each sheet. Report the total of all amounts not entitle priority listed on this Schedule E in the box labeled "Totals" on the last sheet of the completed schedule. Individual debtors with primarily consumer debts report total also on the Statistical Summary of Certain Liabilities and Related Data.	riorit al led t
☐ Check this box if debtor has no creditors holding unsecured priority claims to report on this Schedule E.	
TYPES OF PRIORITY CLAIMS (Check the appropriate box(es) below if claims in that category are listed on the attached sheets)	
☐ Domestic support obligations Claims for domestic support that are owed to or recoverable by a spouse, former spouse, or child of the debtor, or the parent, legal guardian, or responsible re of such a child, or a governmental unit to whom such a domestic support claim has been assigned to the extent provided in 11 U.S.C. § 507(a)(1).	elativ
□ Extensions of credit in an involuntary case Claims arising in the ordinary course of the debtor's business or financial affairs after the commencement of the case but before the earlier of the appointment trustee or the order for relief. 11 U.S.C. § 507(a)(3).	ıt of
☐ Wages, salaries, and commissions Wages, salaries, and commissions, including vacation, severance, and sick leave pay owing to employees and commissions owing to qualifying independent representatives up to \$12,475* per person earned within 180 days immediately preceding the filing of the original petition, or the cessation of business, whicheve occurred first, to the extent provided in 11 U.S.C. § 507(a)(4).	
☐ Contributions to employee benefit plans Money owed to employee benefit plans for services rendered within 180 days immediately preceding the filing of the original petition, or the cessation of bus whichever occurred first, to the extent provided in 11 U.S.C. § 507(a)(5).	sines
☐ Certain farmers and fishermen Claims of certain farmers and fishermen, up to \$6,150* per farmer or fisherman, against the debtor, as provided in 11 U.S.C. § 507(a)(6).	
☐ Deposits by individuals Claims of individuals up to \$2,775* for deposits for the purchase, lease, or rental of property or services for personal, family, or household use, that were not delivered or provided. 11 U.S.C. § 507(a)(7).	t
■ Taxes and certain other debts owed to governmental units Taxes, customs duties, and penalties owing to federal, state, and local governmental units as set forth in 11 U.S.C. § 507(a)(8).	
Commitments to maintain the capital of an insured depository institution Claims based on commitments to the FDIC, RTC, Director of the Office of Thrift Supervision, Comptroller of the Currency, or Board of Governors of the Fec Reserve System, or their predecessors or successors, to maintain the capital of an insured depository institution. 11 U.S.C. § 507 (a)(9).	dera
Claims for death or personal injury while debtor was intoxicated Claims for death or personal injury resulting from the operation of a motor vehicle or vessel while the debtor was intoxicated from using alcohol, a drug, or another substance, 11 U.S. C. 8 507(a)(10)	

another substance. 11 U.S.C. § 507(a)(10).

^{*} Amount subject to adjustment on 4/01/16, and every three years thereafter with respect to cases commenced on or after the date of adjustment.

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 28 of 42

B6E (Official Form 6E) (4/13) - Cont.

In re	SIGA Technologies, Inc.		Case No	14-12623 (SHL)	
•		Debtor			

SCHEDULE E - CREDITORS HOLDING UNSECURED PRIORITY CLAIMS

(Continuation Sheet)

Taxes and Certain Other Debts Owed to Governmental Units

TYPE OF PRIORITY UNLIQUIDATED CODEBTOR Husband, Wife, Joint, or Community AMOUNT NOT ENTITLED TO PRIORITY, IF ANY CREDITOR'S NAME, ONTINGENT SPUTED AND MAILING ADDRESS Н DATE CLAIM WAS INCURRED **AMOUNT** INCLUDING ZIP CODE, W AND CONSIDERATION FOR CLAIM OF CLAIM AMOUNT ENTITLED TO PRIORITY C AND ACCOUNT NUMBER (See instructions.) Account No. See Schedule E Attachment Unliquidated Unliquidated Unliquidated Account No. Account No. Account No. Account No. Subtotal 0.00 Sheet <u>1</u> of <u>1</u> continuation sheets attached to (Total of this page) Schedule of Creditors Holding Unsecured Priority Claims 0.00 0.00 0.00 Total (Report on Summary of Schedules) 0.00 0.00

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case N. G. 29:01 42

Schedule E - Creditors Holding Unsecured Priority Claims

Creditor Name	Address1	Address2	Address3	Address4	City	State	Zip	Country	Date Claim was Incurred and Consideration for Claim	Contingent	Unliquidated	Disputed	Amount of Claim
									Potential Tax				
Benton County Tax Collector	PO Box 964				Corvallis	OR	97339-0964		Liability	Х	Х	Х	Unliquidated
California	Franchise Tax Board	PO Box 942857			Sacramento	CA	94257-0531		Potential Tax Liability	x	х	x	Unliquidated
Camorna	Transmise rax board	1 0 BOX 342037			Sucramento		34237 0331		Potential Tax	Î	^	^	Omiquidated
Corvallis, Oregon	Benton County Tax Office	PO Box 964			Corvallis	OR	97339-0964		Liability	х	х	х	Unliquidated
Delaware Secretary of State	State of Delaware	Division of Corporations	PO Box 5509		Binghamton	NY	13902-5509		Potential Tax Liability	х	x	х	Unliquidated
Kentucky	Kentucky Department of Revenue	501 High St			Frankfort	KY	40620		Potential Tax Liability	х	х	х	Unliquidated
Michigan	Michigan Department of Treasury	PO Box 30774			Lansing	МІ	48909-8274		Potential Tax Liability	х	x	х	Unliquidated
New Jersey	State of New Jersey, Division of Taxation, Revenue Processing Ct	PO Box 666			Trenton	NJ	08646-0666		Potential Tax Liability	х	х	х	Unliquidated
New York City	NYC Department of Finance	Correspondence Unit	One Centre Street	22nd Floor	New York	NY	10007		Potential Tax Liability	х	x	х	Unliquidated
New York	NYS Corporation Tax	Processing Unit	PO Box 22102		Albany	NY	12201-2102		Potential Tax Liability	х	х	х	Unliquidated
Oregon	Oregon Department of Revenue	955 Center St NE			Salem	OR	97301		Potential Tax Liability	x	х	х	Unliquidated
Pennsylvania	PA Department of Revenue	PO Box 280425			Harrisburg	PA	17128-0425		Potential Tax Liability	x	х	х	Unliquidated
Internal Revenue Service	Department of the Treasury	Internal Revenue Service			Ogden	UT	84201-0012		Potential Tax Liability	x	х	х	Unliquidated

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 30 of 42

B6F (Official Form 6F) (12/07)

In re	SIGA Technologies, Inc.		Case No. <u>14-12623 (S</u>	HL)
-		Debtor	,	

SCHEDULE F - CREDITORS HOLDING UNSECURED NONPRIORITY CLAIMS

State the name, mailing address, including zip code, and last four digits of any account number, of all entities holding unsecured claims without priority against the debtor or the property of the debtor, as of the date of filing of the petition. The complete account number of any account the debtor has with the creditor is useful to the trustee and the creditor and may be provided if the debtor chooses to do so. If a minor child is a creditor, state the child's initials and the name and address of the child's parent or guardian, such as "A.B., a minor child, by John Doe, guardian." Do not disclose the child's name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m). Do not include claims listed in Schedules D and E. If all creditors will not fit on this page, use the continuation sheet provided.

If any entity other than a spouse in a joint case may be jointly liable on a claim, place an "X" in the column labeled "Codebtor," include the entity on the appropriate schedule of creditors, and complete Schedule H - Codebtors. If a joint petition is filed, state whether the husband, wife, both of them, or the marital community may be liable on each claim by placing an "H," "W," "J," or "C" in the column labeled "Husband, Wife, Joint, or Community."

If the claim is contingent, place an "X" in the column labeled "Contingent." If the claim is unliquidated, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Disputed." (You may need to place an "X" in more than one of these three columns.)

Report the total of all claims listed on this schedule in the box labeled "Total" on the last sheet of the completed schedule. Report this total also on the Summary of Schedules and, if the debtor is an individual with primarily consumer debts, report this total also on the Statistical Summary of Certain Liabilities and Related Data.

☐ Check this box if debtor has no creditors holding unsecure	ed c	lair	ms to report on this Schedule F.				
CREDITOR'S NAME, MAILING ADDRESS INCLUDING ZIP CODE, AND ACCOUNT NUMBER (See instructions above.)	CODEBTOR	H W J	CONSIDERATION FOR CLAIM. IF CLAIM IS SUBJECT TO SETORE SO STATE	CONTLNGENT	ORL-QU-DAFED	DISPUTED	AMOUNT OF CLAIM
Account No.					Ė	}	
See Schedule F Attachment		-					4,094,583.50
Account No.	Г				П		
Account No.							
Account No.						}	
continuation sheets attached			S (Total of the	ubtenis p			4,094,583.50
			(Report on Summary of Sc		ota lule		4,094,583.50

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case NC 94 32 22 01 42

Schedule F - 1

Creditor Name	Address1	Address2	Address3	City	State	Zip	Country	Date Claim was Incurred, Consideration for Claim, and Whether Claim is Subject to Setoff	Disputed	Amount of Claim
AIRGAS USA, LLC	3125 KATHRYN STREET			ALBANY	OR	97321		VARIOUS – TRADE CLAIM		\$523.00
		ATTN: JULIE	1421 KALAMAZOO							
ALBEMARLE CORPORATION	ALBEMARLE CORPORATION	RISDON	STREET	SOUTH HAVEN	МІ	49090		VARIOUS – TRADE CLAIM		\$2,762,753.35
ALCHEMY SECURITY, LLC		PO BOX 40516		DENVER	со	80204		VARIOUS – TRADE CLAIM		\$81.95
ALIANDA CUENNICAL LINNITED	HELD AT SUITE 2, PORTLAND	CLACIC DOAD					CIRRALTAR	VARIOUS TRADE CLAIM		¢200.00
ALIANN PROC COFFE	HOUSE 1852 FESCUE STREET	GLACIS ROAD		ALBANY	OR	97321	GIBRALTAR	VARIOUS – TRADE CLAIM		\$300.00
ALLANN BROS COFEE AMAZON				ORLANDO	FL	9/321		VARIOUS – TRADE CLAIM		\$178.67 \$1,461.36
AMAZON	PO BOX 965055			ORLANDO	FL			VARIOUS – TRADE CLAIM		\$1,461.36
AMERICAN DREAM PIZZA	2525 NORTHWEST MONROE			CORVALLIS	OR	97330		VARIOUS – TRADE CLAIM		\$30.60
AMERICAN EXPRESS	PO BOX 2855			NEW YORK	NY	10116-2855		VARIOUS – TRADE CLAIM		\$33.87
AMERICAN STOCK TRANSFER & TRUST COMPANY	PO BOX 12893			PHILADELPHIA	PA	19176-0893		VARIOUS – TRADE CLAIM		\$788.00
ANALYSIS GROUP, INC.	111 HUNTINGTON AVENUE	10TH FLOOR		BOSTON	MA	2199		VARIOUS – TRADE CLAIM		\$24,630.50
ANDREW STERN	660 MADISON AVE	SUITE 1700		NEW YORK	NY			VARIOUS – TRADE CLAIM		\$6,969.00
APTUIT SCIENTIFIC OPERATIONS LLC	ATTN: JENNIFER GOLDBERG	3065 KENT AVE.		WEST LAFAYETTE	IN	47906		VARIOUS – TRADE CLAIM		\$34,066.08
ARAMARK UNIFORM SERVICES	PO BOX 21210	SOOS KEIVI AVE.		EUGENE	OR	97402		VARIOUS – TRADE CLAIM		\$98.88
AT&T MOBILITY	PO BOX 1809			PARAMUS	NJ	7653		VARIOUS – TRADE CLAIM		\$36.98
ATAT WOBIETT	I O BOX 1003			WOODSTOCK	143	, 033		VALUE OF THE CENTER		Ş30.30
BAY TACT CORPORATION	440 ROUTE 198			VALLEY	СТ	06282-2427		VARIOUS – TRADE CLAIM		\$659.20
								VARIOUS – CONSULTING		
BDO USA, LLP	ATTN: AZENITH ARAYA	100 PARK AVENUE		NEW YORK	NY	10017		SERVICES		\$4,500.00
		64550 RESEARCH								
BEND RESEARCH	ATTN: MARY HELLER	ROAD		BEND	OR	97701		VARIOUS – TRADE CLAIM		\$5,500.00
BI-MART CORPORATION	PO BOX 2310			EUGENE	OR	97402		VARIOUS – TRADE CLAIM		\$84.01
	ATTN: ALPHONSO TSINIJINNI	ONE FEDERAL								
BINGHAM MCCUTCHEN LLP	DAVID O. JOHANSON	STREET		BOSTON	MA	02110-1726		VARIOUS - LEGAL SERVICES		\$61,427.24
BRUCE SLOVIN	660 MADISON AVE	SUITE 1700		NEW YORK	NY	10065		VARIOUS – TRADE CLAIM		\$6,969.00
CATALENT BUADAMA COLUTIONS	ATTN: JASPREET JABBAL LISA	14 SCHOOLHOUSE		CONTENCE	NI	9973		VARIOUS TRADE CLAIM		\$220.450.44
CATALENT PHARMA SOLUTIONS CENTURYLINK	MARSICANO BUSINESS SERVICES	ROAD PO BOX 52187		SOMERSET PHOENIX	NJ AZ	8873 85072-2187		VARIOUS – TRADE CLAIM VARIOUS – TRADE CLAIM		\$230,159.14 \$283.64
CHEMAXON LLC.	PO BOX 1026	1 O BOX 32107		SALEM	MA	1970		VARIOUS – TRADE CLAIM VARIOUS – TRADE CLAIM		\$680.55
COGENT COMMUNICATIONS, INC.	PO BOX 791087			BALTIMORE	MD	21279		VARIOUS – TRADE CLAIM		\$350.00
COMCAST CABLE	PO BOX 37601			PHILADELPHIA	PA	19104		VARIOUS – TRADE CLAIM		\$48.53
COMPENSATION ADVISORY PARTNERS	ATTN: ILANA KANZAS	1133 AVENUE OF THE AMERICAS, 36TH FLOOR		NEW YORK	NY	10036		VARIOUS – TRADE CLAIM		\$4,737.50
	ATTIN. ILAIVA NAIVAS			INEW TORK	INT	10036		VARIOUS - I RADE CLAIM		\$4,737.50
CONTROL SOLUTIONS INTL	ATTN: KATHI LOFTUS	ATTN: ACCOUNTS RECEIVABLE		CHICAGO	IL	60675-5343		VARIOUS – TRADE CLAIM		\$6,600.00

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case NC 94-322-01 42

Schedule F - 1

Creditor Name	Address1	Address2	Address3	City	State	Zip	Country	Date Claim was Incurred, Consideration for Claim, and Whether Claim is Subject to Setoff	Disputed	Amount of Claim
COOLEY LLP	ATTN: WILLIAM SCHWARTZ	1114 AVENUE OF THE AMERICAS		NEW YORK	NY	10036-7798		VARIOUS - LEGAL SERVICES		\$165,322.53
COOLET LEF	ATTN. WILLIAM SCHWARTZ	3301 KINSMAN		INEW TORK	INT	10030-7736		VARIOUS - LEGAL SERVICES		\$103,322.33
COVANCE LABS	ATTN: JUDY BIERI	BLVD.		MADISON	wı	53704		VARIOUS – TRADE CLAIM		\$34,678.25
	ATTENTION: ACCOUNTING	1201 PENNSYLVANIA								
COVINGTON & BURLING LLP	DEPARTMENT	AVENUE, N.W.		WASHINGTON	DC	20004-2401		VARIOUS - LEGAL SERVICES		\$2,505.00
CYPROTEX	15 BEECH LANE			MACCLESFIELD	SK		UK	VARIOUS – TRADE CLAIM		\$4,430.00
DRINKER BIDDLE & REATH LLP	ONE LOGAN SQUARE	SUITE 2000		PHILADELPHIA	PA	19103-6996		VARIOUS - LEGAL SERVICES		\$7,038.00
FEDERAL EXPRESS	PO BOX 7221			PASADENA	CA	91109-7321		VARIOUS – TRADE CLAIM		\$543.68
FISHNET SECURITY, INC.	ATTN: JANET ASHCRAFT	3701 SOLUTIONS CENTER		CHICAGO	IL	60677-3007		VARIOUS – TRADE CLAIM		\$7,487.50
		2470 NORTH								
FORMUREX INC.	ATTN: SUNNY SUN	WILCOX ROAD		STOCKTON	CA	95215		VARIOUS – TRADE CLAIM		\$12,383.23
FOUR OAKS PARTNERS CONSULTING,										
LLC	7901 STONRIDGE DRIVE	STE 401		PLEASONTON	CA	94588		VARIOUS – TRADE CLAIM		\$50,000.00
								VARIOUS – CONSULTING		
FTI CONSULTING	WALL STREET PLAZA	89 PINE STREET	32ND FL.	MEW YORK	NY	10005		SERVICES		\$20,061.45
GARY SHERMANO	AVAILABLE UPON REQUEST							VARIOUS – TRADE CLAIM		\$1,376.12
GE CAPITAL C/O RICOH USA PROGRAM	PO BOX 650073			DALLAS	TX	75265-0073		VARIOUS – TRADE CLAIM		\$1,748.24
GLOBENEWSWIRE	LOCKBOX 40200	PO BOX 8500		PHILADELPHIA	PA	19178-0200		VARIOUS – TRADE CLAIM		\$952.66
GRM DOCUMENT STORAGE, LLC	PO BOX 35539			NEWARK	NJ	7193		VARIOUS – TRADE CLAIM		\$77.63
GRM INFORMATION MANAGEMENT										
SERVICES	PO BOX 35539			NEWARK	NJ	7193		VARIOUS – TRADE CLAIM		\$728.33
HARVEY & PRICE CO.	PO BOX 1910			EUGENE	OR	97440		VARIOUS – TRADE CLAIM		\$2,052.00
HILTON GARDEN INN CORVALIIS	2500 SW WESTERN BLVD			CORVALLIS	OR	97333		VARIOUS – TRADE CLAIM		\$1,178.10
	RUSSELL BUILDING, BRUNEL SCIENCE PARK, KINGSTON									
HYPHA DISCOVERY LIMITED	LANE			UXBRIDGE		UB8 3PQ		VARIOUS – TRADE CLAIM		\$10,000.00
IDBS INC	1301 MARINA VILLAGE PKWY	SUITE # 320		ALAMEDA	CA	94501		VARIOUS – TRADE CLAIM		\$725.00
INC RESEARCH, LLC	4800 FALLS OF NEUSE ROAD	SUITE 600		RALEIGH	NC	27609		VARIOUS – TRADE CLAIM	1	\$15,040.04
TO THE SERVICE OF THE	TOO THE OF HEAD	55 550				2,303		THE CENTY	+	Ç13,0- 1 0.04
INTEGRA TELECOM, INC.	198 COMMERCIAL ST SE #160			SALEM	OR	97301		VARIOUS – TRADE CLAIM		\$950.17
IRON MOUNTAIN	10950 SW 5TH STREET			BEAVERTON	OR	97005		VARIOUS – TRADE CLAIM		\$5,129.69
JAMES J. ANTAL	660 MADISON AVE	SUITE 1700		NEW YORK	NY	10065		VARIOUS – TRADE CLAIM		\$12,469.00
JEFFREY B. KINDLER	660 MADISON AVE	SUITE 1700		NEW YORK	NY	10065		VARIOUS – TRADE CLAIM		\$6,969.00
JEFFREY R. HINCKS	AVAILABLE UPON REQUEST	232.2,30			1	10005		VARIOUS – TRADE CLAIM	1	\$15,632.93
Z		1099 NEW YORK						THE CENTY	+	Ç13,032.33
JENNER AND BLOCK	ATTN: JAY DEVECCHIO	AVENUE	NW SUITE 900	WASHINGTON	DC	20001		VARIOUS - LEGAL SERVICES		\$7,004.00
JOSEPH W. MARSHALL, III	660 MADISON AVE	SUITE 1700	55.12.500	NEW YORK	NY	10065		VARIOUS – TRADE CLAIM	+	\$40,091.71
300ETT W. MINIOTINES, III	ATTN: JOSEPH SEPTON	880 THIRD AVENUE		THE WORK	141	10003		THIS THE CENTY		Ç 4 0,031.71
KCSA STRATEGIC COMMUNICATIONS	CHRISTOPHER HARRISON	- 6TH FLOOR		NEW YORK	NY	10022		VARIOUS – TRADE CLAIM		\$14,153.72

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case NC 94-32-01 42

Schedule F - 1

Creditor Name	Address1	Address2	Address3	City	State	Zip	Country	Date Claim was Incurred, Consideration for Claim, and Whether Claim is Subject to Setoff	Disputed	Amount of Claim
	1177 AVENUE OF THE									
LLP	AMERICAS			NEW YORK	NY	10036		VARIOUS - LEGAL SERVICES		\$9,422.00
LASER IMAGE	PO BOX 41034			EUGENE	OR	97404		VARIOUS – TRADE CLAIM		\$41.20
LATHAM & WATKINS LLP	PO BOX 7247-8181			PHILADELPHIA	PA	19170		VARIOUS - LEGAL SERVICES		\$270.28
LSN NETWORKS INC.	PO BOX 41034			EUGENE	OR	97404		VARIOUS – TRADE CLAIM		\$510.00
M.L CORRADO MD	ATTN: MICHAEL CORRADO	1309 SEVEN CORNER ROAD		PERKASIE	PA	18944		VARIOUS – TRADE CLAIM		\$10,281.41
MACANDREWS & FORBES GROUP, LLC	35 EAST 62ND STREET			NEW YORK	NY	10065		VARIOUS – TRADE CLAIM		\$3,421.51
		16771 BOONES								
MARANDAS & MCCLELLAN, LLC.	MATTHEW W. MCCLELLAN	FERRY ROAD		LAKE OSWEGO	OR	97035		VARIOUS - LEGAL SERVICES	\perp	\$53.40
								VARIOUS – CONSULTING		
MARION WEINREB & ASSOCIATES, INC.		58 VISTA DEL SOL		MILL VALLEY	CA	94941		SERVICES	\perp	\$7,000.00
MICHAEL J. BAYER	660 MADISON AVE	SUITE 1700		NEW YORK	NY	10065		VARIOUS – TRADE CLAIM		\$12,852.00
NORTHLAND LABORATORIES, INC.	1818 SKOKIE BLVD			NORTHBROOK	IL	60062		VARIOUS – TRADE CLAIM		\$38,413.20
NW NATURAL	220 NW 2ND AVE.			PORTLAND	OR	97209		VARIOUS – TRADE CLAIM		\$12.23
OSTROLENK FABER LLP	1180 AVENUE OF THE AMERICAS			NEW YORK	NY	10036		VARIOUS - LEGAL SERVICES		\$24,000.00
PATHEON MANUFACTURING SERVICES, LLC	ATTN: KAYE BYRD	5900 MARTIN LUTHER KING JR. HWY.		GREENVILLE	NC	27834		VARIOUS – TRADE CLAIM		\$40,866.67
PAUL G. SAVAS	660 MADISON AVE	SUITE 1700		NEW YORK	NY	10065		VARIOUS – TRADE CLAIM		\$10,250.00
PHARSIGHT	ATTN: SEAN P. MULLEN	321 EAST EVELYN AVENUE		MOUNTAIN VIEW	CA	94041		VARIOUS – TRADE CLAIM		\$7,500.00
PHILIP K. RUSSELL M.D	AVAILABLE UPON REQUEST							VARIOUS – TRADE CLAIM		\$565.40
PITNEYBOWES GLOBAL FINANCIAL	PO BOX 371887			PITTSBURGH	PA	15250-7887		VARIOUS – TRADE CLAIM		\$32.00
POWDERSIZE, INC.	20 PACIFIC DRIVE			QUAKERTOWN	PA	18951		VARIOUS – TRADE CLAIM		\$85,075.03
PROFECTUS, INC.	8338 NE ALDERWOOD RD	STE 130B		PORTLAND	OR	97220		VARIOUS – TRADE CLAIM		\$1,520.00
PSC ENVIRONMENTAL SERVICES LLC	625 S. 32ND STREET			WASHOUGAL	WA	98671		VARIOUS – TRADE CLAIM		\$3,880.17
QUENCH	PO BOX 8500	LOCKBOX 53203		PHILADELPHIA	PA	19178-3203		VARIOUS – TRADE CLAIM		\$30.50
QUILL CORPORATION	PO BOX 37600			PHILADELPHIA	PA	19101-0600		VARIOUS – TRADE CLAIM		\$228.17
REPUBLIC SERVICES	PO BOX 1			CORVALLIS	OR	97339		VARIOUS – TRADE CLAIM		\$466.00
		7528 AUBURN								
RICERCA BIOSCIENCES, LLC	ATTN: LORI SEDILKO	ROAD		CONCORD	ОН	44077		VARIOUS – TRADE CLAIM		\$5,910.00
RICOH USA, INC	PO BOX 827577			PHILADELPHIA	PA	19182-7577		VARIOUS – TRADE CLAIM		\$326.59
ROYAL DISPATCH SERVICE, INC.	43-22 VAN DAM STREET	BUILDING 600,		LONG ISLAND CITY	NY	11101		VARIOUS – TRADE CLAIM		\$1,545.90
RWH MYERS & COMPANY LLP	SUMMERFIELD VILLAGE	SUITE 630		PITTSBURGH	PA	15241		VARIOUS – TRADE CLAIM		\$86.25
SEAMLESS NORTH AMERICA, LLC	PO BOX 5439			NEW YORK	NY	10087		VARIOUS – TRADE CLAIM		\$783.00
SENOPSYS LLC	ATTN: JEFF WORTHINGTON	800 WEST CUMMING PARK		WOBURN	MA	1801		VARIOUS – TRADE CLAIM		\$28,275.00
SHAREHOLDER.COM	C/O WELLS FARGO BANK	LOCKBOX 30200		PHILADELPHIA	PA	19178-0200		VARIOUS – TRADE CLAIM	+	\$1,366.00

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document

Schedule F - 1

Creditor Name	Address1	Address2	Address3	City	State	Zip	Country	Date Claim was Incurred, Consideration for Claim, and Whether Claim is Subject to Setoff	Disputed	Amount of Claim
SHARP CLINICAL SERVICES, INC.	300 KIMBERTON ROAD			PHOENIXVILLE	PA	19460		VARIOUS – TRADE CLAIM		\$18,700.00
SHIGA INTERNATIONAL PATENT	GRAN TOKYO SOUTH TOWER 1-									
OFFICE	9-2			MARUNOUCHI		CHIYODA-KU	JAPAN	VARIOUS – TRADE CLAIM		\$4,762.47
SOLOMON-PAGE GROUP LLC	PO BOX 75314			CHICAGO	IL	60675-5314		VARIOUS – TRADE CLAIM		\$16,089.00
SOUTHERN RESEARCH INSTITUTE	431 AVIATION WAY			FREDERICK	MD	21701-4756		VARIOUS – TRADE CLAIM		\$123,929.00
STAPLES	16501 TROJAN WAY			LA MIRADA	CA	90638		VARIOUS – TRADE CLAIM		\$702.87
	ONE STATE STREET PLAZA,									
STERLING INFO SYSTEM, INC	24TH FLOOR			NEW YORK	NY	10004		VARIOUS – TRADE CLAIM		\$21.77
STEVEN FASMAN	AVAILABLE UPON REQUEST							VARIOUS – TRADE CLAIM		\$2,460.00
THE ECONOMIC CLUB OF NEW YORK	350 FIFTH AVENUE, SUITE 4910			NEW YORK	NY	10118		VARIOUS – TRADE CLAIM		\$67.53
THOMAS E. CONSTANCE, ESQ.	660 MADISON AVE	SUITE 1700		NEW YORK	NY	10065		VARIOUS – TRADE CLAIM		\$6,969.00
THUAN TRAN	AVAILABLE UPON REQUEST							VARIOUS – TRADE CLAIM		\$1,320.00
TIME WARNER CABLE	PO BOX 11820			NEWARK	NJ	07101-8120		VARIOUS – TRADE CLAIM		\$58.98
VERIZON	PO BOX 15124			ALBANY	NY	12212-5124		VARIOUS – TRADE CLAIM		\$39.00
VERIZON BUSINESS	PO BOX 660794			DALLAS	TX	75266		VARIOUS – TRADE CLAIM		\$257.34
	ATTN: CORRESPONDENCE									
VERIZON WIRELESS	TEAM	PO BOX 5029		WALLINGFORD	СТ	6492		VARIOUS – TRADE CLAIM		\$4,166.25
VIOGEN BIOSCIENCES	290 WEST 2320 SOUTH	SUITE E		SALT LAKE CITY	UT	84119		VARIOUS – TRADE CLAIM		\$22,677.77
W. V. BUCCELLA, ESQ.	AVAILABLE UPON REQUEST							VARIOUS – TRADE CLAIM		\$2,699.58
								Total:		\$4,094,583.50

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case N. G. 35:01 42 Schedule F-2

Creditor Name	Address1	Address2	Address3	City	State		Date Claim was Incurred, Consideration for Claim, and Whether Claim is Subject to Setoff	Contingent	Unliquidated	Disputed	Amount of Claim
PharmAthene, Inc.	Attn: Linda L. Chang	One Park Place	Suite #450	Annapolis	MD	21401	Litigation	Х	Х	Х	Unliquidated
							Litigation - Surety Bond				
Westchester Fire Insurance Company	436 Walnut Street	WA10G		Philadelphia	PA	19106-3703	(PharmAthene, Inc.)	lχ	х	х	Unliquidated

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 36 of 42

B6G (Official Form 6G) (12/07)

In re	SIGA Technologies, Inc.		Case No. 14-12623 (SHL)
•		Debtor	

SCHEDULE G - EXECUTORY CONTRACTS AND UNEXPIRED LEASES

Describe all executory contracts of any nature and all unexpired leases of real or personal property. Include any timeshare interests. State nature of debtor's interest in contract, i.e., "Purchaser", "Agent", etc. State whether debtor is the lessor or lessee of a lease. Provide the names and complete mailing addresses of all other parties to each lease or contract described. If a minor child is a party to one of the leases or contracts, state the child's initials and the name and address of the child's parent or guardian, such as "A.B., a minor child, by John Doe, guardian." Do not disclose the child's name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m).

☐ Check this box if debtor has no executory contracts or unexpired leases.

Name and Mailing Address, Including Zip Code, of Other Parties to Lease or Contract

Description of Contract or Lease and Nature of Debtor's Interest. State whether lease is for nonresidential real property. State contract number of any government contract.

See Schedule G Attachment

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case P. G. Stockholder G - Executory Contracts and Unexpired Leases Case P. G. Stockholder G - Executory Contracts and Unexpired Leases

										Description of Contract or Lease and Natu
										of Debtor's Interest. State Whether Lease
										for Nonresidential Real Property. State
									Contract Effective	Contract Number of Any Government
Creditor Name	Address1	Address2	Address3	Address4	City	State	Zip	Country	Date	Contract.
BSORPTION SYSTEMS	OAKLANDS CORPORATE CENTER	436 CREAMERY WAY	SUITE 600		EXTON	PA	19341			SERVICE AGREEMENT
CCUNW	2131 NW BIRDSDALE	SE 202ND AVE			GRESHAM	OR	97030			SERVICE AGREEMENT
CE WESTCHESTER	436 WALNUT ST	WA10G			PHILADELPHIA	PA	19106-3703			SURETY BOND
CLAIRO	1950 OLD GALLOWS RD	SUITE 300			VIENNA	VA	22182			SERVICE AGREEMENT
MRGAS	11900 NE 95TH STREET	SUITE 400			VANCOUVER	WA	98682			SERVICE AGREEMENT
LBEMARLE	451 FLORIDA STREET	30111 400			BATON ROUGE	LA	70801			COMMERCIAL MANUFACTURING
ALDEMARLE	431 FLORIDA STREET				BATON ROUGE	LA	70801		8/23/2011	AGREEMENT
ALBEMARLE	451 FLORIDA STREET				BATON ROUGE	LA	70801		11/13/2012	SERVICE AGREEMENT (GENERAL)
ALBRIGHT COLLEGE	1621 N. 13TH STREET				READING	PA	19604		8/25/2014	MATERIAL TRANSFER AGREEMENT
ALCHEMY SECURITY LLC	238 SANTA FE				DENVER	CO	80223		8/15/2011	SERVICE AGREEMENT
ALLAN BROS COFFEE	852 FESCUE ST. SE				ALBANY	OR	97322		6/10/2010	EQUIPMENT LOAN AGREEMENT
ALPHA STATCONSULT LLC	3820 WARTHEN DRIVE				DAMASCUS	MD	20872			CONSULTING AGREEMENT
ALTURAS ANALYTICS, INC	1324 ALTURAS DRIVE				MOSCOW	ID	83843		6/10/2011	SERVICE AGREEMENT
AT&T	208 S. AKARD ST.				DALLAS	TX	75202		12/13/2013	SERVICE AGREEMENT; MAF AFFILIATE AGREEMENT
ATTELLE CEDUICE ACREMANT	FOE KING AVENUE				COLLINADUIC	011	42204		6/20/2011	_
BATTELLE – SERVICE AGREEMENT	505 KING AVENUE			-	COLUMBUS	OH	43201			SERVICE AGREEMENT
BDO USA LLP	100 PARK AVENUE				NEW YORK	NY	10017			SERVICE AGREEMENT
BEND RESEARCH	64550 RESEARCH ROAD				BEND	OR	97701			SERVICE AGREEMENT
BIMART	220 SENECA RD.				EUGENE	OR	97402			COMMERICAL ACCOUNT
BIOTECH PCS	2124 JEFFERSON DAVIS HIGHWAY	SUITE 304			STAFFORD	VA	22554		9/8/2011	CONSULTING AGREEMENT
BIOTECH PCS	2124 JEFFERSON DAVIS HIGHWAY	SUITE 304			STAFFORD	VA	22554		9/13/2011	CONSULTING AGREEMENT
SOSTON UNIVERSITY	85 E. NEWTON ST.	M921			BOSTON	MA	02118		2/21/2013	MATERIAL TRANSFER AGREEMENT
SYRD, CHELSEA	12753 98TH PLACE NE	-			KIRKLAND	WA	98034			CONSULTING AGREEMENT
CATALENT PHARMA SOLUTIONS	10381 DECATUR RD				PHILADELPHIA	PA	19114			SERVICE AGREEMENT; CLINICAL TRIAL
										MATERIAL SHIPMENT
CATALENT PHARMA SOLUTIONS	10381 DECATUR RD				PHILADELPHIA	PA	19114		1/9/2014	SERVICE AGREEMENT; CLINICAL TRIAL MATERIAL SHIPMENT
CATALENT PHARMA SOLUTIONS	1100 ENTERPRISE DR.				WINCHESTER	KY	40391		2/20/2014	SERVICE AGREEMENT; MATERIAL TESTING
CATALENT PHARMA SOLUTIONS	1100 ENTERPRISE DR.				WINCHESTER	KY	40391		4/22/2014	SERVICE AGREEMENT; MATERIAL TESTING
CATALENT PHARMA SOLUTIONS	10381 DECATUR RD				PHILADELPHIA	PA	19114		6/19/2014	SERVICE AGREEMENT; CLINICAL TRIAL
CATALENT DUADANA COLUTIONS	14 SCHOOLHOUSE BOAD			-	COMEDCET	NII	00073		12/15/2014	MATERIAL SHIPMENT
CATALENT PHARMA SOLUTIONS	14 SCHOOLHOUSE ROAD	CLUTE 200N			SOMERSET	NJ	08873			COMMERCIAL SUPPLY AGREEMENT
CBER/FDA (HANA GOLDING)	1401 ROCKVILLE PIKE	SUITE 200N			ROCKVILLE	MD	20852	_		MATERIAL TRANSFER AGREEMENT
CEREP	LE BOIS L'EVEQU	BP1	86600		CELLE L'EVESCAULT			France		SERVICE AGREEMENT
CHARLES RIVER LABORATORIES	251 BALLARDVALE STREET				WILMINGTON	MA	01887			SERVICE AGREEMENT
COMCAST	COMCAST CENTER	1701 JFK BLVD			PHILADELPHIA	PA	19103			SERVICE/SALES AGREEMENT
COVANCE CLINICAL RESEARCH UNIT, NC.	3402 KINSMAN BLVD				MADISON	WI	53704		9/10/2013	SERVICE AGREEMENT
OVANCE LABORATORIES, INC.	3402 KINSMAN BLVD				MADISON	WI	53704		3/1/2013	SERVICE AGREEMENT
SP PHARMA CONSULTING	130 PINE BANK ROAD				FLEMINGTON	NJ	08822			CONSULTING AGREEMENT
CYPROTEX	15 BEECH LANE	MACCLESFIELD			CHESHIRE SK10 2DR	1.45	00022	United Kingdom		SERVICE AGREEMENT
DIAMOND BIOPHARM LIMITED	NO. 4 EAST WING	GEMINI HOUSE	FLEX MEADOW	HARLOW	ESSEX CM19 5TJ		1	United Kingdom		CONSULTING AGREEMENT
DILIGENT BOARD MEMBER SERVICES,	39 WEST 37TH STREET	8TH FLOOR	. LEX.III.ENDOW		NEW YORK	NY	10018			SERVICE AGREEMENT
NC.										
DSM	5900 MARTIN LUTHER KING JR HW	Y			GREENVILLE	NC	27834		1/12/2012	SERVICE AGREEMENT
ARMER, RAINER	AVAILABLE UPON REQUEST								3/18/2013	CONSULTING AGREEMENT
ASMAN, STEVEN	AVAILABLE UPON REQUEST								8/15/2014	CONSULTING AGREEMENT
EDERAL UNIVERSITY MINAS GERAIS, BRAZIL	AV. ANTONIO CARLOS, 6627	PAMPULHA	BELO HORIZONTE MG	CEP 31.270-901				Brazil	4/5/2013	MATERIAL TRANSFER AGREEMENT
EDEX	942 SOUTH SHADY GROVE RD.			1	MEMPHIS	TN	38120		11/7/2011	PRICING AGREEMENT
EDEX CUSTOM CRITICAL, INC.	1475 BOETTLER RD.				UNIONTOWN	ОН	44685			TRANSPORATION SERVICES AGREEMENT

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case P. G. Schedule G - Executory Contracts and Unexpired Leases Case P. G. Schedule G - Executory Contracts and Unexpired Leases

										Description of Contract or Lease and Nature
										of Debtor's Interest. State Whether Lease is
										for Nonresidential Real Property. State
									Contract Effective	Contract Number of Any Government
Creditor Name	Address1	Address2	Address3	Address4	City	State	Zip	Country	Date	Contract.
FISHNET SECURITY, INC.	6130 SPRINT PARKWAY	STE 400			OVERLAND PARK	KS	66211	1	1	SERVICE AGREEMENT
	2470 WILCOX RD	312 400				CA	95215			
FORMUREX, INC.		CLUTTE DOC			STOCKTON					SERVICE AGREEMENT
FORTUNE PERSONNEL CONSULTANTS	2435 LYNN ROAD	SUITE 206			RALEIGH	NC	27612		3///201.	CONSULTING/FEE AGREEMENT
GATLIN, LARRY	AVAILABLE UPON REQUEST									CONSULTING AGREEMENT
GENERAL ELECTRIC CAPITAL CORPORATION	TWO BETHESDA METRO CENTER	SUITE 600			BETHESDA	MD	20814		12/31/2012	LOAN AND SECURITY AGREEMENT
HARDISON, MARK	303 THE WOODS LN				WINCHESTER	KY	40391		1/21/2014	CONSULTING AGREEMENT
HARVEY & PRICE	2015 NUGGET WAY				EUGENE	OR	97403		6/11/2013	SERVICE AGREEMENT
HHS/ASPR/AMCG	330 INDEPENDENCE AVENUE	SW	ROOM G640		WASHINGTON	DC	20201			BARDA CONTRACT
HHS/OS/ASPR/BARDA	330 INDEPENDENCE AVENUE	SW	ROOM G640		WASHINGTON	DC	20201			B BARDA CONTRACT
HIGHTAIL	1919 BASCOM AVENUE	300	NOOW G040		CAMPBELL	CA	95008			SUBSCRIBER AGREEMENT
					CAIVIPBELL	CA	95008			
HINCKS, JEFFREY	AVAILABLE UPON REQUEST									CONSULTING AGREEMENT
HIRE RIGHT	3349 MICHELSON DR.	SUITE 1500			IRVINE	CA	92612			SUBSCRIBER AGREEMENT
HYPHA DISCOVERY LTD	RUSSELL BUILDING	BRUNEL SCIENCE PARK	UXBRIDGE		MIDDLESEX UB8 3PQ			United Kingdom	5/21/2014	SERVICE AGREEMENT
INC RESEARCH	3201 BEECHLEAF COURT	SUITE 600			RALEIGH	NC	27604		6/21/2012	SERVICE AGREEMENT
INTEGRA TELECOM	198 COMMERICAL ST. SE	SUITE 160			SALEM	OR	97301			SERVICE AGREEMENT
INTEGRATED ANALYTICAL SOLUTIONS	1456 FOURTH ST.	UNIT C			BERKLEY	CA	94710			SERVICE AGREEMENT
INTEGRATED BIOTHERAPEUTICS INC	21 FIRSTFIELD ROAD	SUITE 100			GAITHERSBURG	MD	20878		12/3/2012	SERVICE AGREEMENT
IRON MOUNTAIN	1 FEDERAL STREET				BOSTON	MA	02110			SERVICE AGREEMENT; SHRED AGREEMENT
IRON MOUNTAIN	1 FEDERAL STREET				BOSTON	МА	02110		5/19/201:	SERVICE AGREEMENT; STORAGE AGREEMENT
JANIKING	1500 VALLEY RIVER DRIVE	SUITE 205			EUGENE	OR	97404		11/1/2010	SERVICE AGREEMENT
JOHNSON & JOHNSON	410 GEORGE ST.				NEW BRUNSWICK	NJ	08901			MATERIAL TRANSFER AGREEMENT
KASTLE SYSTEMS	205 EAST 42ND ST.				NEW YORK	NY	10017			SERVICE AGREEMENT
						NY	10017			
KASTLE SYSTEMS	205 EAST 42ND ST.				NEW YORK	+				SERVICE AGREEMENT
KCSA STRATEGIC COMMUNICATIONS	880 THIRD AVENUE				NEW YORK	NY	10022		10/1/2009	SERVICE AGREEMENT (INVESTOR RELATIONS)
KINETA FOUR, LLC	219 TERRY AVE. N, SUITE 300				SEATTLE	WA	98109-5208		8/14/2014	ASSET PURCHASE AGREEMENT
KINETA FOUR, LLC	219 TERRY AVE. N, SUITE 300				SEATTLE	WA	98109-5208		8/14/2014	ASSIGNMENT AND ASSUMPTION AGREEMENT
KINETA FOUR, LLC	219 TERRY AVE. N, SUITE 300				SEATTLE	WA	98109-5208		8/14/2014	BILL OF SALE
KINETA FOUR, LLC					SEATTLE	WA				OPERATING AGREEMENT
	219 TERRY AVE. N, SUITE 300						98109-5208			
KINETA FOUR, LLC	219 TERRY AVE. N, SUITE 300				SEATTLE	WA	98109-5208			PROFITS INTEREST UNIT AGREEMENT
LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY	9420 ATHENA CIRCLE				LA JOLLA	CA	92037		8/25/2009	MATERIAL TRANSFER AGREEMENT
LACHMAN CONSULTANT SERVICES	1600 STEWART AVENUE	SUITE 604			WESTBURY	NY	11590		5/19/2011	CONSULTING AGREEMENT
LANCASTER LABORATORIES	2425 NEW HOLLAND PIKE				LANCASTER	PA	17601			SERVICE AGREEMENT
LINK SYSTEMS, INC	ONE DOCK STREET				STAMFORD	СТ	06902	İ		SERVICE AGREEMENT
LOVELACE RESPIRATORY RESEARCH	2425 RIDGECREST DR. SE				ALBUQUERQUE	NM	87108			SERVICE AGREEMENT
INSTITUTE	<u> </u>	1			 	1	+			
LS NETWORKS	921 SW WASHINGTON ST	#370			PORTLAND	OR	97205			SERVICE AGREEMENT
MACANDREWS & FORBES GROUP, LLC	35 EAST 62ND STREET				NEW YORK	NY	10065		4/30/2013	SERVICE AGREEMENT (PROFESSIONAL AND ADMINISTRATIVE)
MACANDREWS & FORBES GROUP, LLC	35 EAST 62ND STREET				NEW YORK	NY	10065		1/9/2013	SUBLEASE AGREEMENT
MACANDREWS & FORBES LLC	35 EAST 62ND STREET				NEW YORK	NY	10065		4/30/2013	COMMON STOCK PURCHASE WARRANT
MARKHAM, RICHARD	615 N. WOLFE STREET				BALTIMORE	MD	21205			MATERIAL TRANSFER AGREEMENT
MCCAIN INSTITUTE	1777 F STREET NW				WASHINGTON DC	.710	20006			MEMORANDUM OF AGREEMENT
				_		NC		 		
METRICS	1240 SUGG PARKWAY				GREENVILLE	NC	27834			SERVICE AGREEMENT
ML CORRADO CONSULTING	1309 SEVEN CORNER RD			_	PERKASIE	PA	18944			CONSULTING AGREEMENT
MWA, INC.	58 VISTA DEL SOL				MILL VALLEY	CA	94941			CONSULTING AGREEMENT
NACR	3344 HWY 149				EAGAN	MN	55121		2/14/2013	SERVICE AGREEMENT
NATIONAL INSTITUTES OF HEALTH	6011 EXECUTIVE BLVD				ROCKVILLE	MD	20852		5/3/201:	NIH GRANT
NELSON LABS, INC.	6280 SOUTH REDWOOD RD				SALT LAKE CITY	UT	84123		7/3/2011	SERVICE AGREEMENT

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case P. G. Schedule G - Executory Contracts and Unexpired Leases Case P. G. Schedule G - Executory Contracts and Unexpired Leases

									Contract Effective	Description of Contract or Lease and Nature of Debtor's Interest. State Whether Lease is for Nonresidential Real Property. State Contract Number of Any Government
Creditor Name	Address1	Address2	Address3	Address4	City	State	Zip	Country	Date	Contract.
NIAID	6610 ROCKLEDGE DR				BETHESDA	MD	20892		8/6/201	NON-CLINICAL EVALUATION AGREEMENT
NIAID	6610 ROCKLEDGE DR	SUITE 2800	MSC 6606		BETHESDA	MD	20892		9/26/201	MATERIAL TRANSFER AGREEMENT
NORTHLAND LABORATORIES	1818 SKOKIE BLVD				NORTHBROOK	IL	60062		6/18/201	SERVICE AGREEMENT
OCEAN TOMO	200 W. MADISON	37TH FLOOR			CHICAGO	IL	60606		8/26/201	4 ENGAGEMENT LETTER AGREEMENT
OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH	6011 EXECUTIVE BOULEVARD	SUITE 325			ROCKVILLE	MD	20852-3804		2/4/2008 BIOLOGICAL MATERIALS LICENSE AGREEMENT	
OREGON HEALTH & SCIENCE UNIVERSITY	505 NW 185TH AVENUE				BEAVERTON	OR	97006		4/13/201	MATERIAL TRANSFER AGREEMENT
OTT, MARY BERNADETTE	6411 STONEY HILL ROAD				NEW HOPE	PA	18938		4/3/201	CONSULTING AGREEMENT
P51 LABS, INC.	1021 NE KIRSTEN PLACE				CORVALLIS	OR	97330		6/23/201	CONSULTING AGREEMENT
PAREXEL	195 WEST STREET				WALTHAM	MA	02451		1/1/201	CONSULTING AGREEMENT
PHARMABRIDGE, INC	3805 OLD EASTON RD				DOYLESTOWN	PA	18902		2/20/201	SERVICE AGREEMENT
PHARMACORE, INC.	4180 MENDENHALL OAKS PARKWAY				HIGH POINT	NC	27265		4/26/201	SERVICE AGREEMENT
PHARSIGHT CORPORATION	210 N. TUCKER BLVD	SUITE 350			ST. LOUIS	МО	63101		5/18/201	SERVICE AGREEMENT
PLANKIS, PETER	2605 NW LINNAN CIRCLE				CORVALLIS	OR	97330		1/24/201	1 CONSULTING AGREEMENT
POLIT BUREAU BVBA	26 KONINGIN ASTRIDLAAN	LANDEN	3400					Belgium	1/28/201	CONSULTING AGREEMENT
POWDERSIZE, INC.	20 PACIFIC DRIVE				QUAKERTOWN	PA	18951		5/1/201	SERVICE AGREEMENT (GENERAL)
POWDERSIZE, INC.	20 PACIFIC DRIVE				QUAKERTOWN	PA	18951		8/15/201	SERVICE AGREEMENT; COMMERCIAL SERVICE AGREEMENT
QUENCH	780 5TH AVENUE	SUITE 110			KING OF PRUSSIA	PA	19406		5/20/201	1 RENTAL AGREEMENT
RESEARCH WAY INVESTMENTS	P.O. BOX 1833 / 1508 OLIVE STREET				PASO ROBLES	CA	93447 / 93446			COMMERCIAL LEASE AGREEMENT
RICERCA	7528 AUBURN ROAD				CONCORD	ОН	44077		9/29/201	1 SERVICE AGREEMENT
RICOH	70 VALLEY STREAM PKWY				MALVERN	PA	19355			B EQUIPMENT LEASE AGREEMENT; MAF AFFLIATE AGREEMENT
RICOH	70 VALLEY STREAM PKWY				MALVERN	PA	19355		5/25/201	EQUIPMENT LEASE AGREEMENT
RICOH	70 VALLEY STREAM PKWY				MALVERN	PA	19355			B EQUIPMENT LEASE AGREEMENT
RICOH	70 VALLEY STREAM PKWY				MALVERN	PA	19355			EQUIPMENT LEASE AGREEMENT
RIGAKU AMERICAS CORPORATION	9009 NEW TRAILS				THE WOODLANDS	TX	77381			MATERIAL TRANSFER AGREEMENT
RISK CONTROL STRATEGIES, INC.	250 N. WESTLAKE BLVD	SUITE 200			WESTLAKE VILLAGE	CA	91362		1/21/201	1 CONSULTING AGREEMENT
ROOT-BERNSTEIN, ROBERT	2174 BIOMEDICAL AND PHYSICAL SCIENCES BLDG	MICHIGAN STATE UNIVERSITY			EAST LANSING	МІ	48824		7/22/200	MATERIAL TRANSFER AGREEMENT
SAFEBRIDGE CONSULTANTS	1924 OLD MIDDLEFIELD WAY				MOUNTAIN VIEW	CA	94043		11/17/200	CONSULTING AGREEMENT
SCHUMACHER, DORIS	11 LOCKHAVEN COURT				BEDMINSTER	NJ	07921			1 CONSULTING AGREEMENT
SCISAFE, INC.	2540 ROUTE 130	SUITE 114			CRANBURY	NJ	08512		2/12/201	SERVICE AGREEMENT
SECUREWORKS (DELL)	1 CONCOURSE PKWY NE				ATLANTA	GA	30328		12/2/200	SERVICE AGREEMENT
SECURITY ALARM CORPORATION	217 MAIN SE				ALBANY	OR	97321		9/2/199	ALARM MONITORING CONTRACT
SENOPSYS	800 WEST CUMMINGS PARK	SUITE 1500			WOBURN	MA	01801		10/28/201	SERVICE AGREEMENT
SEQWRIGHT, INC.	2575 WEST BELLFORT	SUITE 2001			HOUSTON	TX	77054		10/26/201	SERVICE AGREEMENT
SHARP CLINICAL SERVICES, INC. (FORMERLY BILCARE, INC.)	300 KIMBERTON ROAD				PHOENIXVILLE	PA	19460		8/8/201	2 SERVICE AGREEMENT
SHIMADZU	7102 RIVERWOOD DR.				COLUMBIA	MD	21046		9/5/201	MATERIAL TRANSFER AGREEMENT
CONFIDENTIAL SIGA EMPLOYEE #1	AVAILABLE UPON REQUEST									EMPLOYMENT AGREEMENT
CONFIDENTIAL SIGA EMPLOYEE #2	AVAILABLE UPON REQUEST									EMPLOYMENT AGREEMENT
CONFIDENTIAL SIGA EMPLOYEE #3	AVAILABLE UPON REQUEST									EMPLOYMENT AGREEMENT
CONFIDENTIAL SIGA EMPLOYEE #4	AVAILABLE UPON REQUEST									EMPLOYMENT AGREEMENT
CONFIDENTIAL SIGA EMPLOYEE #5	AVAILABLE UPON REQUEST									EMPLOYMENT AGREEMENT
CONFIDENTIAL SIGA EMPLOYEE #6	AVAILABLE UPON REQUEST									EMPLOYMENT AGREEMENT
SOLOMAN-PAGE GROUP LLC	260 MADISON AVENUE				NEW YORK	NY	10016			4 SERVICE AGREEMENT (RECRUITING)
SOUTHERN RESEARCH INSTITUTE	2000 NINTH AVENUE SOUTH				BIRMINGHAM	AL	35205			SERVICE AGREEMENT
SSCI INC (APTUIT)	TWO GREENWICH OFFICE PARK				GREENWICH	СТ	06831			SERVICE AGREEMENT
STERLING-HOFFMAN LIFE SCIENCES	425 UNIVERSITY AVENUE	SUITE 800			TORONTO	Ontario		Canada		CONSULTING/FEE AGREEMENT
STRASSER, JOSEF	1501 REGENTS PARK LANE				GREENSBORO	NC	27455			CONSULTING AGREEMENT
TEICHMAN, SAM	631 HILLGIRT CIRCLE				OAKLAND	CA	94610			CONSULTING AGREEMENT
THOMSON REUTERS (MARKETS) LLC	THE THOMSON REUTERS BUILDING	3 TIMES SQUARE			NEW YORK	NY	10036		8/16/201	SERVICE AGREEMENT (DATABASE SUBSCRIPTION)

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Case P. 40 of 42 Schedule G - Executory Contracts and Unexpired Leases

Creditor Name	Address1	Address2	Address3	Address4	City	State	Zip	Country		Description of Contract or Lease and Nature of Debtor's Interest. State Whether Lease is for Nonresidential Real Property. State Contract Number of Any Government Contract.
THOMSON REUTERS (SCIENTIFIC) LLC	1500 SPRING GARDEN STREET,				PENNSYLVANIA	PA	19130		1/14/2014	SERVICE AGREEMENT (DATABASE
	FOURTH FLOOR									SUBSCRIPTION)
TRAN, THUAN	AVAILABLE UPON REQUEST								12/11/2013	CONSULTING AGREEMENT
TRICLINIC LABS INC.	1201 CUMBERLAND AVE	STE. S			WEST LAFAYETTE	IN	47906		11/5/2012	SERVICE AGREEMENT
TRINET EMPLOYER GROUP, INC.	101 CALLAN AVENUE, THIRD FLOOR				SAN LEANDRO	CA	94577		12/17/1997	SERVICE AGREEMENT (HR)
UNANET	45240 BUSINESS COURT	SUITE 300			DULLES	VA	20166		1/1/2014	SUBSCRIPTION LICENSE
UNIVERSITAT AUTONOMA DE BARCELONA	08193 BELLATERRA	CERDANYOLA DEL VALLES			BARCELONA			Spain	2/11/2013	MATERIAL TRANSFER AGREEMENT
UNIVERSITY AT BUFFALO	402 CROFTS HALL	UNIVERSITY OF BUFFALO			BUFFALO	NY	14260		7/24/2013	MATERIAL TRANSFER AGREEMENT
UNIVERSITY OF HEIDELBERG	IM NEUENHEIMER FELD 672				69120 HEIDELBERG			Germany	6/10/2011	MATERIAL TRANSFER AGREEMENT
VIOGEN BIOSCIENCES	1290 WEST	2320 SOUTH	STE E		SALT LAKE CITY	UT	84119		6/23/2014	SERVICE AGREEMENT
WEBFILINGS LLC	2625 N. LOOP DRIVE	SUITE 2105			AMES	IA	50010		12/23/2011	SUBSCRIPTION AND SERVICES AGREEMENT

14-12623-shl Doc 112 Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 41 of 42

B6H (Official Form 6H) (12/07)

In re	SIGA Technologies, Inc.		Case No. 14-12623 (SHL)
-	Clert recimiologics, me.	Dehtor ,	Cube 110

SCHEDULE H - CODEBTORS

Provide the information requested concerning any person or entity, other than a spouse in a joint case, that is also liable on any debts listed by debtor in the schedules of creditors. Include all guarantors and co-signers. If the debtor resides or resided in a community property state, commonwealth, or territory (including Alaska, Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Puerto Rico, Texas, Washington, or Wisconsin) within the eight year period immediately preceding the commencement of the case, identify the name of the debtor's spouse and of any former spouse who resides or resided with the debtor in the community property state, commonwealth, or territory. Include all names used by the nondebtor spouse during the eight years immediately preceding the commencement of this case. If a minor child is a codebtor or a creditor, state the child's initials and the name and address of the child's parent or guardian, such as "A.B., a minor child, by John Doe, guardian." Do not disclose the child's name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m).

Check this box if debtor has no codebtors.

NAME AND ADDRESS OF CODEBTOR

NAME AND ADDRESS OF CREDITOR

14-12623-shl Doc 112

Filed 10/30/14 Entered 10/30/14 18:22:19 Main Document Pg 42 of 42

B6 Declaration (Official Form 6 - Declaration). (12/07)

United States Bankruptcy Court Southern District of New York

In re	SIGA Technologies, Inc.	Case No.	14-12623 (SHL)	
		Debtor(s)	Chapter	11

DECLARATION CONCERNING DEBTOR'S SCHEDULES

DECLARATION UNDER PENALTY OF PERJURY ON BEHALF OF CORPORATION OR PARTNERSHIP

I, the Executive Vice President and Chief Financial Officer of the corporation named as debtor in this case, declare under penalty of perjury that I have read the foregoing summary and schedules, consisting of ___41__ sheets, and that they are true and correct to the best of my knowledge, information, and belief.

Date October 30, 2014

Signature /s/ Daniel J. Luckshire

Daniel J. Luckshire

Executive Vice President and Chief Financial Officer

SIGA Technologies, Inc.

Penalty for making a false statement or concealing property: Fine of up to \$500,000 or imprisonment for up to 5 years or both. 18 U.S.C. §§ 152 and 3571.